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ABSTRACT 
The stem bark of Peltophorum africanum and Bridelia micrantha are used in South Africa 
traditional medicine for treatment of intestinal parasites, relieve stomach problems and human 
immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS). The growing 
problem of antibiotic resistance by Helicobacter pylori the major etiological agent in gastritis, 
gastric cancer, peptic and gastric ulcer demands the search for novel compounds from plant 
based sources. This study was aimed to determine the antimicrobial activity of five solvent 
(ethylacetate, acetone, ethanol, methanol and water) extracts of the stem bark of P. africanum 
and B. micrantha on clinical strains of H. pylori in a bid to identify potential sources of cheap 
starting materials for the synthesis of new drugs. H. pylori strains were isolated from patients 
presenting with gastric related morbidities at the Livingstone Hospital, Port Elizabeth for 
endoscopy and confirmed following standard microbiology procedures. The plant extracts 
including clarithromycin were tested against 31 clinical strains of H. pylori by the agar well 
diffusion method. The most potent extract was evaluated by the microdilution method to 
determine the Minimum Inhibitory Concentration (MIC50&90), followed by the rate of kill. 
Preliminary phytochemical analysis was carried out. The one way ANOVA test was used to 
statistically analyse the results. All the extracts demonstrated anti-H. pylori activity with zone 
diameters of inhibition that ranged from 0 to 23 mm for the extracts and 0 to 35 mm for 
clarithromycin. Marked susceptibility (100%) was recorded for the ethyl acetate extract of P. 
africanum (P. afr. EA) and the acetone extract of B. micrantha (B. mic. A), which were 
statistically significant (P < 0.05) compared to all other extracts and clarithromycin. For B. 
micrantha ethyl acetate extract, 93.5% susceptibility was observed while for the control 
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antibiotic, clarithromycin it was 58.1%. The MIC50 ranged from 0.0048 to 0.313 mg/mL for P. 
afr. EA, and from 0.0048 to 0.156 mg/mL for B. mic. EA; MIC90 ranged from 0.156 mg/mL to 
0.625 mg/mL and 0.0048 to 2.5 mg/mL for P. afr. EA and B. mic. EA respectively. There was a 
significant statistical difference observed in potency of both P. afr. EA and B. mic. A compared 
to the two antibiotics (P < 0.05). One hundred percent killing by P. afr EA was observed at 0.05 
mg/mL (½ x MIC) and 0.2 mg/mL (2 x MIC) in 66 h for strain PE466C and PE252C 
respectively. For B. mic. EA, 100% killing effect of both strains (PE430C and PE369C) was 
observed at 0.1 mg/mL (2 x MIC) in 66 h. Qualitative phytochemical analysis confirmed the 
presence of alkaloids, flavonoids, steroids, tannins and saponins in the ethyl acetate extracts of 
both plants, which could be a potential template of lead molecule for the design of new anti- 
Helicobacter pylori therapies. 
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CHAPTER ONE 
1.1 INTRODUCTION 
Helicobacter pylori is one of the most common chronic bacterial pathogens of humans. 
Colonization is usually life long and may lead to chronic gastritis, duodenal and peptic ulceration 
and gastric cancer in later life (Konturek, 2004). This Gram-negative curved rod colonizes the 
gastric epithelial surface and withstands the stomach‘s hostile ambience by microaerophilic 
growth capacity (Lynch, 2007). In addition, it produces numerous virulence factors, the most 
important being urease, oxidase and catalase. The major pathogenic factor of this organism 
includes the cytotoxin CagA and VacA which may contribute to the pathogenesis of disease. In 
addition, host factors may also play a pathogenic role, because autoantibodies appear during H. 
pylori infection in certain patients (Pasceri et al., 1998). 
Infections have been reported to be higher in the developing than in developed countries and 
studies have documented high prevalences in Africa including South Africa (Samie, et al; 2007; 
Ndip et al., 2008). The principal reservoir of infection is the human stomach (Go, 2002), 
drinking water (Bunn et al., 2002) and transmission has been epidemiologically linked to person-
to-person contact, and vehicle (e.g., water) (Go, 2002; Bunn et al., 2002). The prevalence of H. 
pylori infection in a community is related to three factors: firstly, the rate of acquisition of 
infection, that is, incidence; secondly, the rate of loss of the infection; thirdly, the prolonged 
persistence of the bacterium in the gastroduodenal mucosa between infection and eradication. 
Variation in the prevalence is dominated by the great differences between communities in the 
incidence of infection during childhood (Pounder and Ng, 1995; Tkachenko et al., 2007). 
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The high prevalence of infection in developing countries is influenced by socioeconomic 
conditions, ethnic background, gender and age (Taverner and Becker, 2006). An average 
prevalence of 38.2% (range 20.0 - 82.0%) was reported in Europe and North America 
(Raghunath et al., 2003). In Africa, 70 to 80% are infected with the organism, and 61 to 100% 
harbour the organism in sub-Saharan Africa (Holcombe, 1992; Ndip et al., 2008). Infection 
occurs more often in younger individuals and among primary school children (50-80%) than in 
adults (50-69%) (Samie et al., 2007). Another study had indicated no significant difference in 
prevalence between rural and urban Africans (Sathar et al., 1994). 
It is known that H. pylori could be eradicated by a combination of therapeutic agents such as 
antibiotics, bismuth subsalicylate, proton pump inhibitors and H2-blockers which has been 
shown to result in ulcer healing, prevention of peptic ulcer recurrence and may also reduce the 
prevalence of gastric cancer in high-risk populations (Hentschel et al., 1993; Sepulveda and 
Coelho, 2002). However, the cure thus achieved is incomplete and undesirable side effects are 
known to occur (Stamatisa et al., 2003). Eradication failure rate remains as high as 5–20% along 
with frequent relapses of gastric ulcers even after the discerned ‗complete healings‘ (Bazzoli et 
al., 1994, Bell et al., 1995; Bayerdörffer et al., 1995). This situation could be attributed to a 
couple of reasons such as lack of penetration of antibiotics into the depth of gastric mucosa, drug 
resistance of the bacterium developed during repeated applications of anti-Helicobacter pylori 
agents and poor compliance on the part of the patient and/or ulcerogenic side-effects of some 
drugs co-administered imperatively for the management of other accompanying diseases 
(Adamek et al., 1998); therefore, alternative available means of eradicating or preventing 
infections is required (O‘Gara et al., 2000). 
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Antibiotic resistance in H. pylori varies according to geographical region. Resistance to 
metronidazole and clarithromycin was reported to be significantly higher globally and mostly in 
females than in males (Glupczynski et al., 2001; Mégraud, 2004; Ndip et al., 2008). Until 
recently, resistance to amoxicillin was considered to be absent or very rare; however, 
amoxicillin-resistant H. pylori strains have now been identified in different countries (Kohanteb 
et al., 2007). For example, amoxicillin resistant strains was reported to be up to 85.6% in 
Cameroon (Ndip et al., 2008), 31% to 45% in Italy, and 41.2% in China (Wu et al., 2000). 
Tetracycline which has also been used extensively as therapy in other types of infection, such as 
non-gonococcal urethritis, in recent years, was reported not resistant in H. pylori therapy not 
until 1996, when Midolo and colleagues observed tetracycline-resistant strains from Australia 
(Midolo et al., 1996). The emerging resistance to antibiotics limits their use in the treatment of 
infections and this problem is encountered more in Africa (Smith et al., 2001; Asrat et al., 2004, 
Sherif et al., 2004).  
On the other hand, the anti-H. pylori activity of traditional herbal medicines has not been 
extensively studied. Accordingly, there is a growing need of finding new anti-H. pylori agents 
that can hopefully eradicate the invasion and presence of resistant strains of H. pylori to avoid 
relapses of gastric ulcer (Li et al., 2005). Phytomedicine has shown great promise in the 
treatment of intractable infectious diseases in Africa (Iwu et al., 1999). It is estimated that plant 
materials are present in or have provided the models for about 50% of Western drugs (Harbone, 
1998), and herbal remedies continue to play a role in the cure of diseases (Tabuti et al., 2003; 
Ndip et al., 2007); however, most of these claims do not have any scientific backing, though 
continuous usage of these plants in the management of infections indicates that the plants may 
contain constituents, which have antibacterial activities. Medicinal plants such as Xanthum 
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brasilicum, Thymus copticum, Ageratum conyzoides, Scleria striatinux and Lycopodium cernua 
have shown promising anti-Helicobacter pylori activities (Nariman et al., 2004; Mahady et al., 
2005; Ndip et al., 2007). 
Some anti-Helicobacter pylori natural products have been reviewed in previous studies, for 
example, oil-macerated garlic constituents, fatty acids and terpenes in Aristolochia paucinervis, 
costunolides in Magnolia sieboldii and some acidic and alkaline constituents in Coptis japonica, 
Eugenia caryophyllata, Magnolia officinalis and Rhus javanica. Several results, along with the 
observation, suggested that a wider range of phytochemicals could be anti-Helicobacter pylori, 
rationalizing the utility and efficacy of traditional medicines in the treatment of gastric ulcers (Li 
et al., 2005). 
The anti-inflammatory properties of several phytomedicines‘ origin, that contain substances like 
phytoestrogens, flavonoids and its derivatives, phytosterol, tocopherol, ascorbic acid, curcumin, 
genistein, and others, can be inhibitors of the molecular targets of pro-inflammatory mediators in 
inflammatory responses (Iwalewa et al., 2007). There are other plants that contain alkaloids, 
tannin, saponins, anthraquinones, triterpenoids and other constituents which have been reported 
to possess a diverse range of bioactivities including anticancer, immunostimulatory, 
antibacterial, antimalarial and antituberculosis activities. Bearing in mind that some of the 
causative organisms such as H. pylori infections and factors responsible for initiating and 
promoting inflammation could be removed or neutralised to suppress the expression of pro-
inflammatory agents and based on the molecular events that lead to inflammation, it has been 
suggested that the process of sustained inflammation that accompanies chronic diseases like 
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gastritis, ulcers and gastric cancer can be ameliorated and possibly even prevented by 
phytomedicines (Iwalewa et al., 2007). 
Peltophorum africanum (Sond Fabaceae), also known as Weeping Wattle in English (Musese                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
in Venda) is a semi-deciduous to deciduous tree of about 15m with a spreading, untidy canopy 
widespread in South Africa. The stem bark has been traditionally employed in South Africa to 
clear intestinal parasites, relieve stomach problems, treat human immunodeficiency virus/ 
acquired immune deficiency syndrome (HIV/AIDS), infertility and a sore liver (Samie et al., 
2005; Bizimenyera et al., 2006).  
Bridelia micrantha (Hochst., Baill., Euphorbiaceae), also known as Coast gold leaf                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
in English (Munzere in Venda) is a semi-deciduous to deciduous tree up to 20 m tall with a dense 
rounded crown and tall, bare stem widespread in South Africa. The stem bark has been 
traditionally employed in South Africa to treat several clinical conditions including intestinal 
parasites, gastritis, salmonellosis and gastro-enteritis, stomach problems, HIV/AIDS, infertility, 
neurosis and psychosis (Bessong et al., 2006; Iwalewa et al., 2007). This plant has been reported 
to possess compounds like friedelin, a-amyrin, gallic acid, luteoforol and also being active 
against Escherichia coli, Klebsiella pneumoniae, Shigella flexneri, Pseudomonas aeruginosa and 
some other organisms (Samie et al., 2005).  
However, to the best of our knowledge, these plants have not been evaluated for their 
antimicrobial activity on clinical isolates of Helicobacter pylori isolated in South Africa, 
especially when this organism is known to exhibit profound heterogeneity compounded by an 
emerging trend of resistance to the current treatment regimen employed in South Africa (Tanih et 
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al., 2010); hence the search of potential sources of cheap starting materials for the synthesis of 
new drugs against the pathogen becomes imperative. 
 
1.2 HYPOTHESIS 
Peltophorum africanum and Bridelia micrantha can provide potent and cheap regimen with anti-
H. pylori activity. 
 
1.3 RESEARCH OBJECTIVES 
1.3.1 Overall objective 
This study was therefore aimed at investigating the anti-Helicobacter pylori activity of 
Peltophorum africanum and Bridelia micrantha on clinical isolates of H. pylori. 
 
1.3.2 Specific objective 
To test our hypothesis we proposed the following specific objectives 
1. Screen the plant extracts for anti-H. pylori activity. 
2. Determine the minimum inhibitory concentration (MIC50&90). 
3. Determine the rate of kill of the plant extracts. 
4. Identify the phytochemical compounds. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 INTRODUCTION 
The discovery of Helicobacter pylori sounds like a chapter taken from the exciting book, 
Microbe Hunters written in 1926 by Paul de Kruif. It marked the discovery of microbes causing 
infectious diseases that ravaged the world‘s population at the time (Konturek, 2004; Lynch, 
2007). H. pylori is one of the most genetically diverse of bacterial species, and is a major cause 
of at least 90% of duodenal ulcers, 70% of gastric ulcers, non-ulcer dyspepsia, gastro-
oesophageal reflux disease, adenocarcinoma of the distal stomach and mucosa-associated 
lymphoid tissue (MALT) lymphoma in many societies (Tanih et al., 2010).  
Despite years of experience with H. pylori treatment, the ideal regimen for treating the infection 
remains elusive. The most effective eradication treatment is the combination of a proton pump 
inhibitor with 2 antibiotics, but many (10-20%) of the patients don‘t get complete eradication of 
the infection. Antibiotic resistance is a major factor affecting the outcome of treatment which is a 
growing global concern that needs public health attention (Mégraud, 2004). This demands the 
search for novel compounds from plant based sources. Medicinal plants have become important 
elements in indigenous medicinal systems and a number of scientific investigations have 
highlighted the importance and contribution of many plant families. Although there are several 
promising lead studies which are for the most part preliminary, additional work is needed before 
any of these treatments can be considered viable alternatives to conventional therapy (Ndip et al., 
2007). 
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2.2 PATHOGENESIS AND CLINICAL MANIFESTATION OF HELICOBACTER 
PYLORI INFECTION 
 Colonization with H. pylori virtually always lead to infiltration of the gastric mucosa in both the 
antrum and corpus with neutrophilic and mononuclear cells. This chronic active gastritis is the 
primary condition related to H. pylori colonization; other H. pylori-associated disorders in 
particular result from intragastric distribution and severity of this chronic inflammatory process 
may depend on a variety of factors, such as characteristics of the colonizing strain, host genetics 
and immune response, diet, and the level of acid production (Kusters et al., 2006). 
Understanding these factors is thus crucial for the recognition of the role of this organism in the 
etiology of upper gastrointestinal pathology. 
Its helicoidal shape and the action of flagella allow it to cross the thick layer of mucus lining the 
stomach. It then binds to Lewis antigens present on host gastric cells, and secrete factors that 
attract and stimulate inflammatory cells, as well as the multifunctional toxin vacA. H. pylori 
produces chemical components in their cell walls that are very much like molecules made by the 
stomach cells of the host which creates a problem for the immune system (Lynch, 2007). Among 
the clinical consequences of this H. pylori-initiated autoimmune process are achlorhydria with 
secondary hypergastrinemia, with or without pernicious anemia, and increased risk for gastric 
enterochromaffin-like cell carcinoids and cancer (Tanih et al., 2008). 
Acute infections with H. pylori may cause a transient clinical illness, characterized by nausea 
and abdominal pain that may last for several days. After these symptoms resolve, the majority of 
people progress to chronic infection. However there is no recognizable symptom complex or 
syndrome that can be ascribed to chronic gastritis, whether or not due to H. pylori. Peptic ulcer 
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often present with dyspepsia. There may be pain at night; some patients report relief of pain with 
food or antacids and a recurrence of pain in two to four hours (Kusters et al., 2006; Tanih et al., 
2008). 
A possible association between H. pylori infection and idiopathic sideropenic anemia has been 
suggested with resolution of anemia observed in some cases after cure of the infection. Another 
interesting clinical manifestation related to H. pylori infection is growth retardation. A Danish 
study involving 1756 women showed that the infection is related to late menarche and has also 
been linked to several skin diseases (Realdi et al., 1999). An association with chronic idiopathic 
urticaria has been proposed with the pathogenic mechanism related to an increase in gastric 
vascular permeability during H. pylori infection, resulting in a greater exposure of the host to 
alimentary allergens. Infection has also been linked to functional vascular diseases; primary 
headache has recently been implicated as related to H. pylori infection (Realdi et al., 1999). 
Respective immunological studies of systemic and local T- and B-cell responses in patients 
chronically infected with H. pylori have shown that the numbers of CD4+ and CD8+ T cells are 
increased in the gastric mucosa of patients with H. pylori gastritis and that T cells isolated from 
the antrum region are able to produce gamma interferon (IFN-) (Appelmelk et al., 1997). Very 
recently, the technique of intracellular staining of cytokines was used to demonstrate that CD4+ 
and CD8+ cells from the antrum region of patients with H. pylori gastritis produce IFN-  but 
nearly no interleukin-4 (IL-4) (Bamford et al., 1998). Far less characterized are immune 
responses in the corpus region of the stomach. Because corpus-predominant H. pylori gastritis is 
associated with the appearance of autoantibodies and atrophic changes, the T-cell response in the 
corpus region may be different (Bamford et al., 1998; Sommer et al., 1998). Studies have shown 
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that infection by more virulent CagA-positive strains of H. pylori is significantly associated with 
ischemic heart disease. These findings strongly suggest that the association between H. pylori 
and ischemic heart disease is related to the virulence of this bacterium (Pasceri et al., 1998). 
 
2.2.1 Gastritis 
Gastritis is mostly due to H. pylori colonization which may be associated with transient 
nonspecific dyspeptic symptoms, such as fullness, nausea, and vomiting, and with considerable 
inflammation of both the proximal and distal stomach mucosa, or pangastritis. This acute phase 
is often associated with hypochlorhydria, which can last for months. It is unclear whether this 
initial colonization can be followed by spontaneous clearance and resolution of gastritis and, if 
so, how often this occurs. When colonization does become persistent, a close correlation exists 
between the level of acid secretion and the distribution of gastritis (chronic gastritis) (Kusters et 
al., 2006). Gastritis is closely related with the activity of free radicals and these oxygen-derived 
free radicals can initiate membrane damage by lipid peroxidation which plays a major 
pathological role in the pathogenesis of gastritis. Natural antioxidants had been justified in the 
treatment of this disease (Demir et al., 2003). 
 
2.2.2 Peptic ulcer disease 
Gastric or duodenal ulcers (commonly referred to as peptic ulcers) are defined as mucosal 
defects with a diameter of at least 0.5 cm penetrating through the muscularis mucosa. Gastric 
ulcers mostly occur at the transition from corpus to antrum mucosa while duodenal ulcers usually 
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occur in the duodenal bulb, which is the area most exposed to gastric acid. Initial reports from all 
over the world in the first decade after the discovery of H. pylori, indicated that approximately 
95% of duodenal ulcers and 85% of gastric ulcers occurred in the presence of H. pylori infection. 
Complications of ulcer disease include bleeding, perforation, and stricture formation. Bleeding is 
the most common complication of ulcer disease and is estimated to occur in 15 to 20% of ulcers 
(Demir et al., 2003; Kusters et al., 2006). 
 
2.2.3 Non-ulcer dyspepsia 
 H. pylori plays a role in the etiology of dyspeptic symptoms of upper gastrointestinal distress 
which may have a reflux-like character, with heartburn and regurgitation as predominant signs; 
may appear dysmotility-like, with early satiety and nausea; or may be ulcer-like, with pain and 
vomiting. Thirty to 60% of patients with functional dyspepsia carry H. pylori and for patients 
with uninvestigated dyspepsia, H. pylori test-and-treat strategy may be an appropriate option 
(Talley and Hunt 1997). 
 
2.2.4 Gastric cancer 
Gastric cancer is one of the most common cancers worldwide, ranking fourth in overall 
frequency, and accounting for over 870,000 new cases and over 650,000 deaths annually, which 
is second only to lung cancer and more frequently in men than in women (Carl-McGrath et al., 
2007). Tumors of the stomach may be either malignant (cancerous) or benign (non-cancerous) 
and can be classified based on gross morphological and histopathological features. Almost all 
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malignant tumors of the stomach are epithelial in origin and can thus be classified as 
adenocarcinomas. Several factors are suspected to play a role in gastric carcinogenesis, including 
the effects of diet, exogenous chemicals, intragastric synthesis of carcinogens, genetic factors, 
infectious agents and pathological conditions in the stomach (such as gastritis) (Stadtlander and 
Waterbor, 1999). Evidence that H. pylori increases the risk of gastric cancer development via the 
sequence of atrophy and metaplasia originates from various studies and it has been estimated that 
this organism colonization increases the risk approximately 10-fold and therefore designated a 
class I carcinogen by the WHO (Kusters et al., 2006). These bacteria play a role in 53% of 
gastric cancer cases in developing countries and in 60% in developed countries (Stadtlander and 
Waterbor, 1999). 
 
2.2.5 Gastric MALT lymphoma 
Gastric low grade B cell lymphomas arising from mucosa associated lymphoid tissue (MALT) 
are the most frequent lymphomas among those located in the primary digestive tract. There is 
now evidence supporting the role of H. pylori infection in the development of these gastric 
lymphomas (GLs). Indeed, H. pylori provide the antigenic stimulus which is mediated by 
mucosal T cells for sustaining growth of gastric MALT lymphoma. The morphological hallmark 
of MALT GL is proliferation of centrocytic-like cells and epithelial destruction that causes 
lymphoepithelial lesions detected on histological examination and the initial stage of tumour may 
also affect the results of treatment (Ruskoné-Fourmestraux et al., 2001). The histological criteria 
for the diagnosis of MALT lymphoma and the differentiation from polyclonal reactive infiltrates 
remain controversial. In particular, diagnosis is based on histological appearance during routine 
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microscopy and on demonstration of clonality by immunohistochemistry or molecular 
techniques, such as PCR; nearly all MALT lymphoma patients are H. pylori positive (Parsonnet 
et al., 2004; Kusters et al., 2006). 
 
2.2.6 Gastroesophageal reflux disease (GERD) 
Helicobacter pylori has been demonstrated as the causative factor of various gastrointestinal 
diseases; nevertheless, the relationship between its infection and gastroesophageal reflux disease 
is still debated (Grande et al., 2008). However, further studies suggested that H. pylori might 
protect against the development of this disease and as such also be of benefit to their hosts. This 
slowly emerging concept came from repeated observations of a low prevalence of H. pylori 
among GERD patients, particularly of more virulent strains (Kusters et al., 2006). It was 
suggested that H. pylori could contribute to GERD through different mechanisms: cardias 
inflammation causing sphincter weakness; increased acid secretion due to antral gastritis; 
delayed gastric emptying and cytotoxin production causing esophageal epithelium injury 
(Grande et al., 2008). 
 
2.3 EPIDEMIOLOGY 
2.3.1 Prevalence of Helicobacter pylori 
The prevalence of H. pylori infection in a community is related to three factors: firstly, the rate 
of acquisition of infection, that is, incidence; secondly, the rate of loss of the infection; thirdly, 
the prolonged persistence of the bacterium in the gastroduodenal mucosa between infection and 
eradication. The onset of infection is from childhood, which once established may persist 
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throughout life (Ndip et al., 2004; Tanih et al., 2009; Dube et al., 2009). However, from a study 
in Tanzania, seropositivity rose steeply with age from 76% in children aged 0 - 4 years to 99% in 
adults (Mbulaiteye et al., 2006). In another study in Egypt, a high prevalence (72.38%) of 
infection was noted among school children (Mohammad et al., 2008).  
In Bloemfontein, South Africa, a study detected a high prevalence (67 - 84%) of H. pylori 
antibodies in children (Dube et al., 2009). In yet another study, H. pylori IgG antibodies were 
also detected from South African children and their mothers (Mosane et al., 2004) and in 
KwaZuluNatal, 76% of Africans were seropositive and more than 50% of African children were 
infected by the age of 10 years. In Ivory Coast, 55% of children aged less than 10 years have 
been reported to be infected. In Cameroon, Nigeria and the Gambia, 50% of children less than 5 
years are infected (Ndip et al., 2004; Tanih et al., 2009). 
The prevalence of infection is greater in developing countries and is influenced by 
socioeconomic conditions, ethnic background, gender and age (Taverner and Becker, 2006). An 
average prevalence of 38.2% (range 20.0 - 82.0%) was reported in Europe and North America 
(Raghunath et al., 2003). In Africa, 70 to 80% are infected with the organism and 61 to 100% 
harbour the organism in sub-Saharan Africa (Holcombe, 1992; Ndip et al., 2008). In Nigeria, a 
prevalence of 73% - 84% was reported as opposed to 92.2% in Cameroon (Mustapha et al., 
2007; Ndip et al., 2008). Prevalence rates of 75 - 85% were reported in Ghana, Kenya and 
Zimbabwe (Mustapha et al., 2007). In the Republic of South Africa, a prevalence of 83.3% was 
reported in Mpumalanga and 50.6% in Venda (44.5% in female and 58.6% in male) (Fritz et al., 
2006; Samie, et al; 2007). 
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2.3.2 Risk factors and transmission of H. pylori  
Transmission of H. pylori probably occurs mostly by the faecal- oral and oral- oral routes and via 
recently contaminated food and water and unclean hands. Variation in the prevalence of infection 
between and among populations suggest that parameters such as age, cultural background, 
genetic predisposition, socio-economic status and environmental factors all play a role in the 
acquisition and transmission of the organism (Tanih et al., 2008). The first, and most frequent, 
mode of transmission is iatrogenic, in which tubes or endoscopes that have been in contact with 
the gastric mucosa of one individual are used for another patient (considered to be marginal) and 
usually occupationally transmitted from a patient to endoscopists and gastroenterologists 
themselves (van Duynhoven and de Jonge, 2001). 
H. pylori has been detected in saliva, vomitus, dental plaque, gastric refluxate and feces. DNA 
fingerprinting studies have confirmed the similarity of strains from children and those from their 
mothers thereby suggesting a possibility of mother-to-child transmission. Intraspecific 
transmission from mother to child has been linked to premastication of food (Kusters et al., 
2006; Dube et al., 2009). Several studies have reported the presence of H. pylori DNA in 
environmental water sources, but this probably reflects contamination with either naked DNA or 
dead H. pylori organisms. To our knowledge there is only a single report of H. pylori being 
successfully cultured from water, but this involved wastewater and as such may well represent 
fecal contamination of the water source (Kusters et al., 2006). 
Increasing consumption of food items has been linked as a risk factor in the prevalence rates of 
H. pylori infection. For instance a marginal association was found between consumption of chili 
and H. pylori prevalence as it is commonly believed in some regions that those who eat chili are 
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prone to develop peptic ulcer disease (Rodolfo et al., 1998). Evaluation of dietary factors 
suggested that eating food from street vendors might be implicated in the acquisition of the 
infection. Fruits that are peeled shortly before consumption are specially recommended for 
travelers as a means to decrease the risk of acquiring intestinal infections (Rodolfo et al., 1998; 
Herbarth et al., 2001; Cardinale et al., 2005). 
Studies of the potential of an animal reservoir led to investigation of risk factors in persons 
working with animals, which suggested that abattoir workers are more frequently seropositive 
than other people working in the same environment. However, studies of meat as a possible 
vehicle showed that vegetarians and populations that abstain from eating either pork or beef 
show no difference in seropositivity than those with less restricted diets (Feldman et al., 1998). 
 
2.4 LABORATORY DIAGNOSIS 
2.4.1 Collection of biopsy specimens 
The best specimens to culture H. pylori from are gastric biopsies obtained during endoscopy. The 
number of biopsies needed to diagnose infection is a subject of controversy. A single biopsy 
specimen taken from the antrum (2 cm from the pylorus) gives good sensitivity but is not 
sufficient for a reliable diagnosis. Indeed, H. pylori may have a patchy distribution, and the more 
biopsy specimens analyzed, the higher the chance of detection. The recommendation is, 
therefore, to take two biopsy specimens from the antrum as well as two specimens each from the 
anterior and posterior corpus. There are some rare cases where the infection lies only in the 
corpus, but usually, H. pylori is present in all sites. After consumption of antisecretory drugs, the 
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corpus may be the only site which remains positive. Biopsy specimens for culture must be taken 
before specimens for histological examination, the latter being introduced in a fixative, otherwise 
there is a risk of transferring small amounts of fixative to the container for biopsy specimens to 
be used for culture (Megraud and Lehours, 2007). 
Antibiotics and bismuth, when used in suboptimal therapy, can suppress but not eliminate the 
organism. Therefore, the patient should not have used these agents for several weeks prior to the 
test. Following inadequate therapy, the organism may regrow in a patchy manner and may not be 
detected by random biopsies. Care must be taken to ensure that the patients did not receive 
antibiotics or antisecretory drugs, especially proton pump inhibitors (PPI), omeprazole, as this 
drug has been shown to inhibit growth of the organism. Although PPI have no direct 
antimicrobial effect at the concentration present in the gastric mucosa (Megraud et al., 1991), 
they indirectly interfere with their distribution in the stomach by changing the pH of its niche, 
leading to its disappearance in the antrum. It is recommended not to consume these drugs 2 
weeks prior to endoscopy. Obviously, the impact also depends on the dose and length of 
treatment; a single dose will not be as detrimental as a substantial acid suppression. Other ulcer 
drugs, e.g., sucralfate, have not shown any effect (Megraud and Lehours, 2007). 
 
2.4.2 Microbiological isolation of the organism 
In most instances, the bacteria are not distributed homogeneously in the biopsy specimens, 
therefore grinding of biopsy is the first and mandatory step in H. pylori isolation. Comparison of 
culture performed with or without grinding showed a higher number of colonies after grinding, 
although the number of positive specimens did not change (Goodwin et al., 1985). In growing 
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this organism, the media components should include an agar base, growth supplements, and 
selective supplements. Most agar bases e.g., brain heart infusion agar, Columbia agar, and 
Wilkins Chalgren agar are satisfactory for growing the organism (Ndip et al., 2003).  
For growth supplement, it is mandatory to add blood or serum, which includes numerous 
nutrients (vitamins and oligoelements, etc.) that enhances growth. The proportion of blood or 
serum can be 5, 7, or preferably, 10%. Red blood cells can be lysed for these growth substances 
to be more readily available. Animal blood, e.g., sheep and horse blood, can be added. Different 
selective supplements containing antimicrobial compounds have been proposed: vancomycin or 
teicoplanin to inhibit Gram-positive cocci; polymyxin, nalidixic acid, colistin, trimethoprim, or 
cefsulodin to inhibit Gram-negative rods; and nystatin or amphotericin B to inhibit fungi. The 
Dent supplement, a modification of Skirrow's formula in which cefsulodin replaces polymyxin 
and amphotericin B is added, is commercially available (Ndip et al 2003; Megraud & Lehours, 
2007).  
Lack of nutrients can result in H. pylori losing its spiral shape and becomes progressively 
coccoidal, which most investigators believe these forms are both nonculturable and nonviable. 
However, others claim that some of them may be viable but nonculturable and constitute a 
resistant form of the bacterium (Benaissa et al., 1996; Kusters et al., 1997). Colonies can survive 
on plates for a week provided they are kept in a microaerobic atmosphere at 4°C. For long-term 
preservation, bacteria must be frozen at a low temperature (–70°C freezer or liquid nitrogen). 
Different broth media have been used, always with a cryoprotective agent, such as glycerol. The 
freezing-thawing process is always deadly for the bacteria, and only a small proportion survives. 
For this reason, it is mandatory to use bacteria in their exponential growth phase, as they are 
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more likely to survive. Frozen H. pylori specimens can be maintained for decades at –70°C 
(Spengler et al., 1992; Ndip et al., 2003; Tanih et al., 2010). 
 
2.4.3 Biochemical characterization 
Identification of cultured bacteria consists essentially of testing for the presence of certain 
enzymes: cytochrome oxidase, catalase, and urease (Konturek, 2004; Samie et al; 2007) and 
eventually {gamma}-glutamyl transpeptidase, leucine aminopeptidase, and alkaline phosphatase. 
Aminopeptidases and esterases (C4 to C12) are also present. The family Helicobacteraceae is 
comprised of the genera Helicobacter and Wolinella. Helicobacteraceae and 
Campylobacteraceae are in the Epsilonproteobacteria, according to the latest edition of Bergey's 
Manual. Cytochrome oxidase is present in all members of the Epsilonproteobacteria. It is usually 
detected with special reagents (Tetramethyl-p-phenylenediamine hydrogen chloride), or a strip 
with coated end, which when rubbed on the colony produced colour changes after 10 to 15 
seconds. Catalase is also present in all Helicobacters and most members of the 
Campylobacteraceae and is detected by introducing a loopful of bacteria into a drop of hydrogen 
peroxide and observing abundant production of bubbles. Nevertheless, catalase-negative mutants 
of H. pylori have been discovered (Westblom et al., 1992). Urease is definitely the most 
important enzyme for identification. H. pylori produces large amounts of urease. To survive in 
its particular ecological niche, H. pylori produces large amounts of this enzyme to buffer the 
acidic medium and creates a microenvironment. When a loopful of the organism is put in contact 
with a few drops of urease medium, the color change occurs instantaneously regardless of the 
formulation. Other diagnostic tests are indeed either strictly based on urease, like the rapid urease 
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test and urea breath test, or partially based, like serology and PCR, which may target urease 
genes (Megraud & Lehours, 2007). 
 
2.5 TREATMENT AND CONTROL 
2.5.1 Antibiotic resistance patterns 
Numerous treatment trials for H. pylori have been described using different antimicrobials, either 
singly or in combination, along with other drugs such as bismuth compound, ranitidine or 
omeprazole. Early treatment studies showed that many antibiotics were able to clear H. pylori, 
however, long term follow-up studies showed that the organism was extremely difficult to 
eradicate. Certainly, eradication of the organism would be considered beneficial in preventing 
gastritis, ulcers, and cancer; there may be other, as yet unknown adverse effects on infected 
children, such as retarded growth or loss of energy (Megraud, 2004). Furthermore, if antibiotics 
are used so extensively, it is very likely that the target bacteria would develop resistance to 
effective drugs within a few years. Prolonged treatment alters the normal microbial population of 
the gastrointestinal tract, eliminating some beneficial bacteria as well as pathogens (Abdul et al., 
2001; Megraud, 2004).  
Antibiotic resistance in H. pylori varies according to geographical region. During recent years, 
resistance to antibiotics, especially metronidazole, has emerged as the major cause of treatment 
failure in most developing countries (Mégraud, 2004) and in South Africa, 96% resistance has 
been observed in metronidazole (Tanih et al., 2010). In general, combined therapy is used to 
eradicate H. pylori infection (Suerbaum & Michetti, 2002), however, increase in the resistant 
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isolates highlights the need for susceptibility testing of H. pylori isolates prior to treatment 
(Mendonca et al., 2000). Resistance to metronidazole and clarithromycin was reported to be 
significantly higher globally and mostly in females than in males, while resistance to 
clarithromycin were significantly higher in children and teens (Glupczynski et al., 2001; Ndip et 
al., 2008).  
Amoxicillin is the only β-lactam used to treat H. pylori infection and it is included in most 
current therapeutic regimens. Until recently, resistance to amoxicillin was considered to be 
absent or very rare; however, amoxicillin-resistant H. pylori strains have now been identified in 
different countries (Kohanteb et al., 2007). Tetracycline resistance in H. pylori was not reported 
until 1996, when Midolo and colleagues reported tetracycline-resistant strains from Australia 
(Midolo et al., 1996). Tetracycline was a component of the bismuth-based triple-therapy regimen 
recommended in the 1990s for treating H. pylori infection, and has also been used extensively as 
therapy in other types of infection, such as non-gonococcal urethritis, in recent years. Whether 
the mechanism of tetracycline resistance is related to carriage of resistance plasmids, originating 
from other bacterial species, remains to be determined (Wu et al., 2000). 
 Susceptibility testing of H. pylori strains reported globally revealed that sensitivity for 
clarithromycin, tetracycline, amoxicillin and metronidazole ranged from 24 - 100% (Megraud, et 
al., 1999; Mégraud, 2004). Global resistance to
 
these antibiotics was reported to be 0 to 100% for 
clarithromycin, 9 to 100% for metronidazole, 0 to 87.1% for tetracycline and 0 to 100% for 
amoxicillin. In Africa, resistance ranged from 60 - 100%, 4 - 100%, 2.5 – 100%, 1.9 – 87.1% and 
in Europe 14.5 - 46%, 1.7 – 28%, 0 – 1.1% and 0 – 5.6% for metronidazole, clarithromycin, 
amoxicillin and tetracycline respectively. In Asia and the Middle East, it was reported to range 
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from 9 – 62.7%, 0 – 27%, 0 – 36.1%, 0 – 5.3% while in South and North America, it ranged 
from 18 – 80%, <4 – 50%, 0 – 18% and 0% for metronidazole, clarithromycin, amoxicillin and 
tetracycline respectively (Njume et al., 2009). 
 
2.5.2 Alternative approaches to treatment 
Treatment of H. pylori infection using antibiotic is not without risk. Antibiotic therapy can lead 
to the development of pseudomembranous colitis, a potentially severe infection caused by 
Clostridium difficile. In addition, antibiotics frequently enable the overgrowth of Candida 
albicans, which can result in vaginitis, gastrointestinal disturbances, or other complaints. 
Moreover, it could lead to the overgrowth of antibiotic-resistant strains of H. pylori, making 
further attempts at eradication more difficult. Because of these risks, most physicians elect to 
treat H. pylori infection only in situations in which the benefits of doing so have been proven 
(e.g., peptic ulcer). If safer alternatives were available to eradicate H. pylori, then a case could be 
made that all such infections should be treated because of the possibility that the risk of gastric 
cancer would be reduced or that nutritional status would be improved.  
Several naturally occurring substances have been investigated as potential alternatives for the 
treatment of H. pylori infection. Although there are several promising leads, these studies are for 
the most part preliminary, and additional work is needed before any of these treatments can be 
considered viable alternatives to conventional therapy (Gaby, 2001; Ndip et al., 2007).  
Bismuth, although not an antibiotic per se, is capable of suppressing the growth of H. pylori. In 
addition, antibiotic resistance does not occur with bismuth therapy, as it can with metronidazole 
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and clarithromycin (Gaby, 2001). The use of pharmacogenomics as an individualize medication 
regimen had also been suggested and demonstrated (TEC, 2008). Preventive care and Making 
lifestyle changes, such as avoiding the long-term use of irritants (aspirin, anti-inflammatory 
drugs, coffee, and alcohol) will go a long way to preventing gastritis and its complications like 
an ulcer.  
Vaccination has become one of the most promising approaches against H. pylori infection (Li et 
al., 2007). At present, most vaccines against H. pylori in animal models have been studied using 
whole-cell preparation, native or recombinant proteins from H. pylori and mucosal adjuvant. In 
general, these vaccines are based on a ‗natural‘ form of the pathogen by lysating and inactivating 
the organism (Del Giudice et al., 2001). In response to H. pylori infection, the host triggers 
vigorous humoral and cellular immune response. Though H. pylori specific antibodies have been 
detected at high titers both in inflamed gastric mucosa and in serum, the infection is still 
persistent and even for a life time, suggesting that H. pylori can evade both innate and adaptive 
immune responses and the immune responses triggered by H. pylori in nature are not optimal to 
eliminate the pathogen (Baldari et al., 2005). Important protective antigens of H. pylori, such as 
VacA, Lpp20, Catalase, CagA, and Urease have been selected and identified which have been 
reportedly used to produce monoclonal antibodies by the hybridoma technique using 
recombinant Catalase–GST as the immunogen and therefore immunoscreened against phage-
displayed random dodecapeptide library. More mimotopes need to be identified and 
characterized in order to optimize the combination presentation of multi-mimotopes to develop 
an efficient vaccine for H. pylori (Li et al., 2007). 
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Stress reduction through relaxation techniques including yoga, tai chi, and meditation can also be 
quite helpful. Eating a diet (Allium vegetables, particularly garlic (Allium sativum L.), Capsaicin 
(hot pepper) consumed as a flavoring spice, Cranberry (Vaccinium macrocarpon) natural fruit, 
(native to North America) high in fiber may not only cut the risk of developing ulcers in half, but 
fiber-rich foods may also speed the healing of ulcers. Fruits and vegetables are particularly 
protective sources of fiber and seem to reduce the amount of inflammation in the lining of the 
stomach; fruit juice appears to have this benefit as well. Fat in the diet may also increase the risk 
of gastritis (Alternative Medicine, 2008; Manyi-Loh et al., 2010).  
Honey-derived remedies constitute a potential source of new compounds that may be useful in 
the management of H. pylori infections (Ndip et al., 2007; Manyi-Loh et al., 2010). It contains 
approximately, 35% glucose, 40% fructose, 5% sucrose, 20% water, enzymes, amino acids, 
organic acids, polyphenols (flavonoids and phenolic acids) and carotenoid-like substances, 
Maillard reaction products, vitamins, ascorbic acids, ά-tocopherol and minerals. However, honey 
contains these natural antioxidants which exhibit a wide range of biological effects, including 
antibacterial, anti-inflammatory, anti-allergic, antithrombotic and vasodilatory actions (Manyi-
Loh et al., 2010). 
 
2.5.3 Medicinal plants: potential alternative approach to the treatment of H. pylori 
infections 
Plant cells fundamentally are chemical factories and many possess a rich supply of 
therapeutically useful constituents with significant biological effects on humans. The use of 
medicinal plants in the treatment of diseases is an ancient tradition that has co-existed with 
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human habitation especially where modern drugs are not affordable, inaccessible or unacceptable 
(Njume et al., 2009). There are many herbs, some of which may be recommended by an herbal 
specialist for symptoms of gastritis, ulcers and other gastrointestinal disorders majorly caused by 
H. pylori infections. Some of such herbs are: Astragalus (Astragalus membranaceus), Barberry 
(Berberis vulgaris), Bilberry (Vaccinium myrtillus), Cat's Claw (Uncaria tomentosa), Cranberry 
(Vaccinium spp.), Ginger (Zingiber officinale), Green Tea (Camellia sinensis), Licorice 
(Glycyrrhiza glabra) e.t.c. They should, therefore, be used with caution and only under the 
guidance of a professionally trained and qualified herbalist as herbs may cause side effects or 
interact with medications (Ndip et al., 2007; Alternative Medicine, 2008). Herbal medicines 
form a significant part of culture and traditions of rural people in developing countries and as a 
result, there is an increasing trend to integrate traditional medicine with primary healthcare 
(Njume et al., 2009). 
 
2.5.3.1 Peltophorum africanum (Sond, Fabaceae) 
Peltophorum africanum also known as Weeping Wattle, is a semi-deciduous to deciduous tree of 
about 15m with a spreading, untidy canopy widespread in South Africa. All parts of this plant 
has been reported to constitute flavonoids, gallic and chlorogenic acid with reported medicinal 
uses. Leaves and bark have been traditionally employed to clear intestinal parasites and relieve 
stomach problems; the stem bark is used to treat colic, diarrhoea, dysentery, helminthosis, human 
immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS), venereal diseases 
and infertility; and roots are used to heal sore throat, wounds and toothache (Iwalewa et al., 
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2007; Theo et al., 2009). It has also been reported to be active against E. coli, S. aureus, A. 
hydrophila, S. sonei and C. jejuni (Samie et al., 2005). 
The roots of this plant traditionally give a very effective remedy for pregnant women when the 
foetus kicks heavily and causes pain to the mother. But this remedy is prepared only if the 
problem lasts at least for two to three days. The outer skin of the roots is scraped away, the roots 
are cut into pieces, put into cold water and heated until it cooks, then the roots are removed. One 
cup of the cooled down infusion is drunk. The same infusion also stops heavy bleeding while 
giving birth. The roots are also used for treating cough with blood and tuberculosis (TB). They 
are soaked in water and slightly heated. The bark provides a cure for treating a sore liver. The 
bark is boiled and the decoction is then drunk. This will induce vomiting that is said to clean the 
liver and relieve pain. It is also used to treat eyes (Bizimenyera et al., 2006). 
 
2.5.3.2 Bridelia micrantha (Hochst., Baill., Euphorbiaceae) 
Bridelia micrantha (Euphorbiaceae), native to sub-Saharan Africa is a semi-deciduous to 
deciduous tree up to 20 m tall with a dense rounded crown and tall, bare stem. All parts of the 
plant are used in traditional medicine in the treatment of stomach ailments and diseases such as 
gastritis, salmonellosis, gastro-enteritis, diarrhea and constipation, tapeworms and as an emetic 
for poisons (causes vomiting) (blackherbals.com). Recent studies show that Bridelia micrantha 
root, stem bark and leaf constitutes friedelin, epi-friedelin, flavonoids, tannins, gallic acid, sterol, 
saponin, anthocyanidin, caffeic acid, taraxerone and taraxerol (a phytochemical found in 
dandelions and seaweed to name a few), which is used in producing anti-cancer drugs. 
Taraxerol-3B-acetate improves tolerance of exercise, removes fatigue and is an anti-aging, anti-
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tumour, hepatoprotective, an antineoplastic agent and an immune stimulator (Bessong et al., 
2005; Iwalewa et al., 2007). This plant has been reported to be active against E. coli, K. 
pneumoniae, S. flexneri, and P. aeruginosa (Samie et al., 2005). 
Scientific studies have shown that extracts of the whole stem demonstrate antimicrobial activity 
by inhibiting the growth of Campylobacter jejuni/coli. It is used as a treatment for skin problems 
such as ulcers, boils and rashes; for respiratory problems such as persistent cough, TB, 
pneumonia, bronchitis and pleurisy; as an analgesic (pain reliever); as an antimalarial; for 
toothache and gum diseases; for painful menstruation; to prevent abortion; as a stimulant and 
restorative tonic (alternative) for fortifying pregnant women; for sickle cell anemia, HIV/AIDS; 
and also used traditionally in Africa to treat psychological problems such as neurosis and 
psychosis and protection against enemies. Preliminary research on medical properties of B. 
micrantha has shown this herb to be beneficial in treating HIV/AIDS as it cures diarrhea and 
stomach discomfort, which are common illnesses in AIDS and contributes to the well-being of 
the patient. It has also been shown to be a possible principle inhibitor to HIV-1 reverse 
transcriptase (FAO, 1986; Hines and Eckman, 1993; Bessong et al., 2005).  
The stem bark decoction is reportedly taken as a remedy for stomach-ache and tapeworm. The 
bark is also boiled to make a soup for treating diarrhoea in children, or is mixed with milk and 
drunk as a tonic. A decoction of roots is drunk to cure aching joints. The leaf sap is used as an 
application to sore eyes and, in a decoction with a number of other plants, for the treatment of 
conjunctivitis. The root is used as a remedy for severe epigastric pain and is applied to the scalp 
to relieve headache. A decoction of the root is drunk as a purgative, an anthelmintic or an 
antidote for poison, as it causes vomiting or diarrhoea that gets rid of the poison. An infusion 
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made from the root is taken orally for coughs. The powdered bark is applied to burns to speed 
healing (FAO, 1986; Hines and Eckman, 1993). 
 
2.5.3.3 Solvents mostly used in plant extractions 
Previous studies have shown that the solvents used in extraction affect the antimicrobial 
activities of plants. A variety of extractants are used for their ability to solubilize anti-microbials 
and also other factors from plants. The type of solvent used may have an effect on the nature of 
the compounds extracted and the resulting bioactivity of the extract, therefore implying that 
some bioactive components can only be extracted by polar solvents while others by less polar 
and yet some by non-polar solvents (Bizimenyera et al., 2006; Ndip et al., 2007). Methanol 
extracts of Ekebergia senegalensis, a common Senegalese plant widely used in folk medicine, 
showed marked antibacterial activity than the petroleum spirit extracts. Water extracts of 
Plumbago zeylanica have also demonstrated lower anti-Helicobacter pylori activity than that of 
organic solvents (Ndip et al., 2007; Njume et al., 2009).  
Many studies have revealed that the ethyl acetate extract of plants is the most active against H. 
pylori and other organisms compared with the other solvents used. For example, the study of 
Theo et al. (2009) demonstrated a good activity of the ethyl acetate extract of P. africanum 
against HIV-1. Also, Maoela et al. (2009) worked on Carpobrotus mellei and Carpobrotus 
quadrifidus; common South African plants widely used in folk medicine and reported marked 
activity with the ethyl acetate extract compared to the chloroform and butanol extracts. On the 
other hand, acetone was mostly selected as a suitable extractant as it extracts compounds of a 
wide polarity range, is miscible with organic and aqueous solvents, and is non-toxic to test 
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organisms. It has been noted that organic solvents extract more plant material than water. 
Besides, acetone extracts the larger amounts of material from plants compared to ethanol, 
dichloromethane, methanol, hexane and water (Bizimenyera et al., 2006) which was also the 
case in this study. Djipa et al. (2000) and Asha et al. (2008) reported best antimicrobial activity 
by acetone extract against pathogenic bacteria compared to other solvent used.  
These may be due to the fact that the active compounds against bacteria strains (e.g. H. pylori) in 
most plants were less polar as non-polar solvents dissolve non-polar compounds best and 
different solvents extract different compounds. Organic solvents were therefore observed to be 
better for more consistent extraction of antimicrobial substances from medicinal plants compared 
to other solvents (Abu-Shanab et al., 2006). To ascertain the value of each extractant therefore, 
several parameters, including the rate of extraction, the quantity extracted, the diversity of 
compounds extracted, the diversity of inhibitory compounds extracted, the ease of subsequent 
handling of the extracts, toxicity of the solvent in the bioassay process and the potential health 
hazard of the extractants have to be evaluated. The efficiency of extraction has to be optimized to 
ensure that as many of the potentially active constituents as possible are extracted (Njume et al., 
2009). 
 
2.5.3.4 Potential anti-H. pylori compounds mostly isolated from plants 
Flavonoids (or bioflavonoids), also collectively known as Vitamin P and citrin are synthesized 
by the phenylpropanoid metabolic pathway in which the amino acid phenylalanine is used to 
produce 4-coumaroyl-CoA. They have been referred to as "nature's biological response 
modifiers" because of strong experimental evidence of their inherent ability to modify the body's 
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reaction to allergens, viruses, and carcinogens (Justesen and Knuthsen, 2001). They show anti-
allergic, anti-inflammatory, anti-microbial and anti-cancer activity. The huge increase in 
antioxidant capacity of blood seen after the consumption of flavonoid-rich foods is not caused 
directly by the flavonoids themselves, but most likely is due to increased uric acid levels that 
result from expelling flavonoids from the body and the process of gearing up to get rid of 
unwanted compounds induces so-called Phase II enzymes that also help to eliminate mutagens 
and carcinogens, and therefore may be of value in cancer prevention. Flavonoids could also 
induce mechanisms that help kill cancer cells and inhibit tumor invasion (Filippos et al., 2007). 
Gallic acid is an organic acid, also known as 3,4,5-trihydroxybenzoic acid, found in gallnuts, 
sumac, witch hazel, tea leaves, oak bark e.t.c. and mostly found both free and as part of tannins. 
Gallic acid is commonly used in the pharmaceutical industry. It is used as a standard for 
determining the phenol content of various analytes by the Folin-Ciocalteau assay; results are 
reported in gallic acid equivalents. Gallic acid can also be used as a starting material in the 
synthesis of the psychedelic alkaloid mescaline and with anti-fungal and anti-viral properties. As 
an antioxidant, it helps to protect our cells against oxidative damage and also found to show 
cytotoxicity against cancer cells, without harming healthy cells. Gallic acid is used as a remote 
astringent in cases of internal haemorrhage, to treat albuminuria and diabetes; also some 
ointment used to treat psoriasis and external haemorrhoids contain gallic acid (Pathak et al., 
2004). 
Chlorogenic acid is a family of naturally occurring organic compounds, esters of cinnamic acids 
and (-)-quinic acid. It is an important biosynthetic intermediate (lignin) and one of the phenols 
found in coffee, in the bamboo Phyllostachys edulis as well as many other plants and  long 
  
31 
 
known as an antioxidant, it also slows the release of glucose into the bloodstream after a meal. It 
is also an inhibitor of the tumor promoting activity of phorbol esters and might contribute to the 
prevention of Type 2 diabetes mellitus and cardiovascular disease. It is claimed to have antiviral, 
antibacterial and antifungal effects with relatively low toxicity and side effects, alongside 
properties that do not lead to antimicrobial resistance (Clifford et al., 2003). 
Many plant species are rich in sterols and sterolines which have been credited to have immuno-
modulatory effects and boost the vitality of AIDS patients. B. micrantha and P. africanum 
investigated herein are generally used among the VhaVendas of South Africa to cure diarrhea 
and stomach discomfort, common illnesses in AIDS (Bessong et al., 2006). Bioassay-guided 
fractionation carried out on the roots and stem-bark of Peltophorum africanum afforded the 
known compounds bergenin and catechin and a red coloured gallotannin. Structural information 
gathered by MALDI-Tof, LC/MS, silylation and acid hydrolysis of the gallotannin indicated that 
it is composed of meta-depside chains of gallic and protocatechuic acids esterified to a 1-O-
isobutyroly-β-d-glucopyranose. Gallotannins are examples of plant polyphenols, and some 
researchers have proposed that polyphenols and tannins are responsible for apparent inhibitory 
properties in enzyme systems, since polyphenols precipitate proteins from solution, and therefore 
the activity of such compounds against enzymes may be non-specific (Bessong et al., 2005). 
Some of these naturally occurring bioactive substances with antioxidant properties, such as plant 
phenols, vitamins, carotenoids, phytoestrogens and terpernoids also have been shown to have 
anti-inflammatory activity and may play an important role in disease prevention and immune 
promotion, especially in chronic inflammatory diseases. Based on the molecular events that lead 
to inflammation, it has been suggested that the process of sustained inflammation that 
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accompanies chronic diseases can be ameliorated and possibly even prevented by 
phytomedicines (Iwalewa et al., 2007). 
The study previously conducted by Li et al. (2005) on Eugenia caryophyllata, Abrus 
cantoniensis and Saussurea lappa had led to the characterization of volatile oil (mainly contains 
eugenol and caryophyllen), a chromone C-glucoside, elagitennins, phytosterols and among these 
plant constituents, eugenol was disclosed to have prominently antibacterial properties (anti-
Helicobacter pylori). In these plants had also been found compounds like triterpenic saponins, 
anthraquinones, alkaloids, flavonoids, and some other constituents such as abrin, abrussic acid, 
uric acid, glabrolide sesquiterpenes, monoterpenes, triterpenes, and aromatic compounds. 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 BACTERIAL STRAINS 
A total of 31 strains of H. pylori in addition to a control strain, NCTC 11638 were subjected to 
antimicrobial assays in this study. Strains were isolated from patients presenting with gastric 
related morbidities at the Livingston Hospital, Port Elizabeth for endoscopy and confirmed 
following our previously reported scheme (Ndip et al., 2008). Informed consent was obtained 
from the patients and ethical approval (Protocol number EcDoH-Res 0002) from the Eastern 
Cape Department of Health, and the institutional review board of the University of Fort Hare 
(GMRDC). 
 
3.2 PREPARATION OF PLANT EXTRACTS 
The stem bark of P. africanum and B. micrantha were selected based on ethnobotanical 
information. The plants were collected in Limpopo Province and identified in collaboration with 
botanist at the University of Venda, Limpopo Province where voucher specimens (number BP01 
& BP03 respectively) have been deposited.  
The method described by Ndip et al. (2007) was employed with modifications. Briefly, the 
plants were harvested, washed, air dried for 2 weeks and ground to fine powder using a blender 
(ATO MSE mix, 702732, England). Technical grade ethylacetate, acetone, ethanol, methanol 
(100%) and water were employed for extraction. Dried plant materials, 2 kg were macerated in 
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five fold excess of the solvent in extraction bottles such that the level of the solvent was above 
that of the plant materials. The slurry was put in a shaker incubator (Edison, N.J., USA) 
regulated at room temperature (RT) for 48 h then centrifuged at 3000 rpm for 5 mins (Model TJ-
6 Beckman, USA) and filtered using filter paper of pore size 60
Å
. The process was repeated 
twice for a total of three extractions (exhaustive extraction) for each solvent. The combined 
extracts were concentrated in a rotavapor (BUCHI R461, Switzerland) and transferred to 
appropriately labeled vials and allowed to stand at RT to permit evaporation of residual solvent. 
A 6.2 gram sample of each plant extract was used for the preliminary bioassay, and 13.8g kept in 
the extract bank. Stock solutions were prepared by dissolving the extracts in 10% Dimethyl 
Sulphoxide (DMSO) which we established to be non inhibitory to H. pylori. 
 
3.3 SCREENING OF CRUDE EXTRACTS FOR ANTI – H. PYLORI ACTIVITY 
The agar-well diffusion method was used as previously described (Boyanova et al., 2005; Ndip 
et al., 2007). Brain Heart Infusion (BHI) agar (Oxoid, England) supplemented with 7% horse 
blood (Oxoid, England) and Skirrow‘s supplement (Oxoid, England) was used. H. pylori 
inoculum was prepared from subcultures of bacteria as follows: four to five colonies of the 
isolates were emulsified in sterile distilled water and the turbidity adjusted to 1.5 × 10
8
 CFU/mL 
(corresponding to 0.5 McFarland standards). A sterile cotton swab was dipped into the 
standardized bacterial suspension and used to evenly inoculate the BHI agar plates. The plates 
were allowed to dry for 3 to 5 min. Wells were punched in the plates using a sterile
 
stainless 6 
mm cork borer. The wells were filled with 30 µL of the extract (50 mg/mL). DMSO
 
(10%) was 
used as a negative control and 0.05 µg/mL clarithromycin as a positive control. The tests were 
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repeated in duplicate and the plates incubated microaerophilically at 37 °C for
 
72 h (Anaerocult 
Basingstoke, England). The diameters of the zones of inhibition were measured in
 
millimeters. 
H. pylori control strain NCTC 11638 inoculated plate was included in all the experiments. 
 
3.4 DETERMINATION OF MIC50 & MIC90 
Test for MIC was carried out as described by Banfi et al. (2003) with modifications. Extracts that 
gave a zone of inhibition ≥14 mm were chosen for MIC determination by the microdilution test 
method in 96-well plates. Two-fold dilutions of the most potent extracts; ethyl acetate extracts of 
Peltophorum africanum (P. afri EA) and Bridelia micrantha (B. mic. EA), acetone extract of 
Bridelia micrantha (B. mic. A) and antibiotics, metronidazole and amoxicillin were prepared in 
the test wells in complete BHI broth (Oxoid, England) supplemented with 7% horse serum 
(Oxoid, England) and Skirrow‘s supplement (Oxoid, England); the final extracts and antibiotics 
concentrations ranged from 0.0048 - 10mg/mL respectively. Each strain was sub-cultured in 
2mL of BHI broth for 2 days and the turbidity adjusted by adding 0.5mL to 4.5mL of normal 
saline and then serially diluted to correspond to 0.5 McFarland standards. Twenty-five 
microliters of each bacterial suspension was added to 175 μL of extract-containing culture 
medium. Control wells were prepared with culture medium and bacterial suspension only. Also 
included was culture medium and extract only at different concentrations. The plates were sealed 
and incubated under microaerophilic condition at 37°C for 3 days. After incubation, 32μL of 
resazurin solution was added per well, colouring them blue. Plates were incubated at 37°C for 
additional 1 h. Plates were observed for colour change from blue to pink in live H. pylori -
containing wells and then read with a microtiter plate reader adjusted to 620nm (Model 680 Bio-
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Rad, Japan). The lowest concentration of the extract resulting in inhibition of 90% & 50% of 
bacterial growth were recorded as the MIC90 & MIC50 respectively. 
 
3.5 DETERMINATION OF THE RATE OF KILL 
Assay for the time and extent of killing of bacterial isolates by P. afri EA and B. mic. EA were 
determined in accordance with previously established methods (Ali et al., 2005; Akinpelu et al., 
2009). Briefly, the turbidity of an 18 h old test organism was first standardized to 10
8
cfu/mL. A 
0.5 mL volume of known cell density from each strain suspension was added to 4.5 mL of BHI 
broth supplemented with 7% horse serum and Skirrow‘s supplement (Oxoid, England) and then 
adjusted for the inclusion of different concentrations of the solution of the extracts (½ x MIC, 
MIC, 2 x MIC and 4 x MIC). These were incubated at 37
o
C in a microaerophilic cabinet shaking 
at ~120 rpm and the killing rate determined over a period of 72 h at 6 h interval (0, 6, 12, 18, 24, 
30, 36, 42, 48, 54, 60, 66, 72 h). Exactly 0.5 mL volume of each suspension was withdrawn at 
time intervals and transferred to 4.5 mL of BHI broth recovery medium containing 3% ―Tween 
80‖ to neutralize the effects of the antimicrobial compound carryovers from the test organisms. 
The suspension was then serially diluted and plated out for viable counts. The plates were later 
incubated microaerophilically at 37
o
C for 72 h. The control plates contained the bacterial cells 
without the extract. The emergent bacterial colonies were counted and compared with the counts 
of the culture control. 
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3.6 PHYTOCHEMICAL ANALYSIS 
Adopting the methods of Adegboye et al. (2008), the qualitative phytochemical analysis of the 
ethyl acetate extract of B. micrantha and P. africanum were carried out as follows: 
 
3.6.1 Test for alkaloids 
Approximately 0.5 g of the plant extract was dissolved in 5 mL of 1% HCl on steam bath. A 
milliliter of the filtrate was treated with few drops of Dragendorff‘s reagent. Turbidity or 
precipitation was taken as indicative of the presence of alkaloids. 
 
3.6.2 Test for flavonoids 
A 0.2 g of the extract was dissolved in 2 mL of methanol and heated. A chip of magnesium metal 
was added to the mixture followed by the addition of a few drops of concentrated HCl. The 
appearance of a red or orange colouration was indicative of the presence of flavonoids. 
 
3.6.3 Test for tannins 
About 1.0 g of the plant extract was dissolved in 10 mL of distilled water and filtered (Acrodisc 
syringe filter, Pall USA). Two to three drops of 10% FeCl3 was added to 2 mL of the filtrate. A 
blackish-blue colouration was indicative of tannins. To another 2 mL of the filtrate was added 1 
mL of bromine water. A precipitate was also taken as positive for tannins. 
  
38 
 
3.6.4 Test for steroids 
A small sample of ethyl acetate extract was dissolved in methanol, spotted on a Thin Layer 
Chromatography (TLC) silica gel 60 F254 plate (Merck) and developed in chloroform: methanol 
(4:1) solvent system. The plate was air-dried and sprayed with concentrated sulphuric acid before 
heating and the development of black spots was recorded as positive for steroids.  
For more confirmation of the presence of steroids, approximately 0.5 g of the extract was 
dissolved in 3 mL of CHCl3 and filtered (Acrodisc syringe filter, Pall USA). To the filtrate was 
added concentrated H2SO4 to form a lower layer. A reddish brown colour was taken as positive 
for steroid ring. 
 
3.6.5 Test for saponins 
Two grams of the extract was boiled in 20 mL of distilled water in a water bath and filtered 
(Acrodisc syringe filter, Pall USA). Approximately 10 mL of the filtrate was mixed with 5mL of 
distilled water and shaken vigorously for a stable persistent froth. The frothing was mixed with 3 
drops of olive oil and shaken vigorously, then observed for the formation of an emulsion. 
 For confirmation of the presence of saponins, Columbia blood agar medium supplemented with 
7% blood was freshly prepared and wells were made in it. The extract dissolved in ethyl acetate 
(and methanol) was applied. Distilled water, methanol and ethyl acetate were used as negative 
control while commercial saponin (BDH) solution (dissolved in distilled water, methanol and 
ethyl acetate) was used as positive control. The plates were incubated at 37
0
C for 6 hrs. 
Complete haemolysis of the blood around the extract was indicative of the presence of saponins. 
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3.7 STATISTICAL ANALYSIS 
Analysis was performed using SPSS Version 17.0 (Illinois USA, 2009). The one way ANOVA 
test was used to determine if there was any statistically significant difference in the diameter of 
zones of inhibition of the plant extracts and clarithromycin; the MIC of the most active extracts 
(P. afri EA, B. mic. EA and B. mic. A) and the control antibiotics (metronidazole and 
amoxicillin). P-values <0.05 were considered significant. 
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CHAPTER FOUR 
RESULTS 
4.1 ANTI-HELICOBACTER PYLORI ACTIVITIES 
Our results on P. africanum showed that the zones of inhibition ranged from 17 to 23 mm for 
ethyl acetate extract; 0 to 21 mm for acetone; and 8 to 15 mm for methanol (Tables 1 & 2), while 
for B. micrantha it was 12 to 20 mm for the ethyl acetate extract; 16 to 23 mm for acetone; and 0 
to 15 mm for water (Tables 3 & 4); the control antibiotic, clarithromycin had a zone diameter of 
0 to 35 mm (Tables 2 & 4). An inhibition zone of ≥14 mm was chosen as representative of 
bacterial susceptibility to the extracts and antibiotic. DMSO (10%) and ethyl acetate (20%) used 
as negative control, showed no activity. 
Of the 31 strains subjected to the plant extracts and antibiotic, 100% susceptibility was recorded 
for the P. afr. EA and B. mic. A. For P. afr., susceptibility to acetone, methanol and water 
extracts were 6.5%, 16.1%, and 25.8%, respectively while for B. mic. 93.5%, 3.2%, and 12.9% 
were noted for ethyl acetate, methanol and water extracts respectively. For the control antibiotic, 
clarithromycin it was 58.1% (Figures 1 and 2). The mean difference of the ethyl acetate extract 
of P. africanum and acetone extract of B. micrantha were statistically significant (P < 0.05) 
compared to the other extracts (except B. mic. EA.) and clarithromycin at 95% confidence 
interval. 
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Table 1: Antibacterial activity of plant extracts (P. africanum) against Helicobacter pylori 
strains. 
 
Zone diameter of inhibition of growth (mm) 
 
 
H. pylori      
strains 
P.afr. (EA) P.afr. (A) P.afr. (E) P.afr. (M) P.afr. (W)      Clr. 
       
PE11A 20 9 10 8 9 10 
PE26A 18 9 11 8 9 18 
PE93A 17 8 10 13 0        28 
PE93C 20 0 12 9 9 8 
PE102C 20 0 8 8 9 16 
PE115A 19 0 11 8 11 10 
PE155A 19 8 9 13 9 15 
PE162A 20 8 10 8 9 35 
PE219C 18 0 0 10 15 12 
PE252C 20 8 10 12 11 15 
PE258C 18 8 12 8 15 10 
PE265C 19 8 8 8 14 13 
PE296C 17 0 12 13 8 0 
PE308C 18 9 13 13 0 15 
PE369A 18 10 8 11 14 20 
PE369C 21 9 7 14 12 18 
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PE402A 23 11 11 14 13 12 
PE406C 19 21 10 14 12 27 
PE407C 19 9 8 11 12 13 
PE411C 19 9 9 9 13 17 
PE430A 22 9 11 11 12 21 
PE430C 18 8 10 9 15 31 
PE436A 19 8 11 12 15 23 
PE436C 22 10 11 12 12 20 
PE462A 18 8 8 12 12 18 
PE462C 20 10 10 12 12 17 
PE466C 18 9 8 12 12 25 
PE467A 20 8 10 11 14 0 
PE467C 20 14 12 15 12 0 
PE469C 21 12 10 14 15 8 
PE471A 20 8 10 13 9 0 
 
 
P.afr., Peltophorum africanum; EA, Ethyl acetate; A, Acetone; E, Ethanol; M, Methanol; W, Water; Clr., 
Clarithromycin. 
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Table 2: Mean zone diameter of inhibition of the crude extract (P. africanum) and antibiotic. 
 
Extract / control antibiotic 
 
Mean zone diameter (mm) 
 
Inhibition diameter range 
 
P.afr. (EA) 
 
19.35±1.450 
 
17 – 23 mm 
P.afr. (A) 8.00±4.359 0 – 21 mm 
P.afr. (E) 9.68±2.329 0 – 13 mm 
P.afr. (M) 11.13±2.262 8 – 15 mm 
P.afr. (W) 11.10±3.664 0 – 15 mm 
Clr. 15.32±8.852 0 – 35 mm 
   
P.afr., Peltophorum africanum; EA, Ethyl acetate; A, Acetone; E, Ethanol; M, Methanol; W, Water; Clr., 
Clarithromycin. 
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Table 3: Antibacterial activity of plant extracts (B. micrantha) against Helicobacter pylori 
strains. 
 
 
Zone diameter of inhibition of growth (mm) 
 
 
        H. pylori 
         strains 
B.mic. (EA) B.mic. (A) B.mic. (E) B.mic. (M) B.mic. (W)         Clr.  
        
         PE11A 16 22 0 0 8 10  
         PE26A 17 22 8 8 10 18  
         PE93A 18 20 0 0 0           28  
         PE93C 18 20 0 8 9  8  
PE102C 16 20 0 0 11 16  
PE115A 17 20 0 0 11 10  
PE155A 16 20 0 0 9 15  
PE162A 12 22 0 8 10 35  
PE219C 18 20 0 0 11 12  
PE252C 20 20 0 0 11 15  
PE258C 15 21 8 8 10 10  
PE265C 16 22 0 0 9 13  
PE296C 14 21 0 0 9 0  
PE308C 19 21 0 0 10 15  
PE369A 13 20 0 12 13 20  
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PE369C 16 20 7 11 12 18  
PE402A 14 22 0 11 15 12  
PE406C 16 21 7 10 13 27  
PE407C 17 23 0 10 12 13  
PE411C 15 20 0 0 13 17  
PE430A 18 18 10 0 12 21  
PE430C 17 19 0 8 15 31  
PE436A 14 16 0 0 10 23  
PE436C 15 22 8 8 14 20  
PE462A 15 21 8 12 13 18  
PE462C 16 21 8 8 10 17  
PE466C 17 17 0 10 13 25  
PE467A 16 20 7 10 14 0  
PE467C 16 20 0 12 13 0  
PE469C 17 20 7 8 13 8  
PE471A 16 21 7 14 9 0  
 
 
B.mic., Bridelia micrantha; EA, Ethyl acetate; A, Acetone; E, Ethanol; M, Methanol; W, Water; Clr., 
Clarithromycin. 
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Table 4: Mean zone diameter of inhibition of the crude extract (B. micrantha) and antibiotic. 
 
Extract / control antibiotic 
 
Mean zone diameter (mm) 
 
Inhibition diameter range 
 
B.mic.  (EA) 
 
16.13±1.708 
 
12 – 20 mm 
B.mic.  (A) 20.39±1.476 16 – 23 mm 
B.mic.  (E) 2.74±3.794 0 – 10 mm 
B.mic.  (M) 5.68±5.108 0 – 14 mm 
B.mic.  (W) 11.03±2.811 0 – 15 mm 
Clr. 15.32±8.852 0 – 35 mm 
   
B.mic., Bridelia micrantha; EA, Ethyl acetate; A, Acetone; E, Ethanol; M, Methanol; W, Water; Clr., 
Clarithromycin. 
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*, No. of strains; * Sus, Susceptible; * Res, Resistance 
Figure 1. Plant extracts (P. africanum) and antibiotic susceptibility against 31 strains of H. 
pylori. 
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*, No. of strains; * Sus, Susceptible; * Res, Resistance 
Figure 2. Plant extracts (B. micrantha) and antibiotic susceptibility against 31 strains of H. 
pylori. 
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4.2 MIC50 AND MIC90 DETERMINATION 
Since P. afr. EA, B. mic. EA and B. mic A. were the most potent, their MIC50 and MIC90 were 
determined against the 31 strains alongside the antibiotics. The MIC50 for P. afr. EA & B. mic. A 
ranged from 0.0048 mg/mL - 0.313 mg/mL, and 0.0048 - 0.156 mg/mL for B. mic. EA, 
metronidazole and amoxicillin respectively. On the other hand, the MIC90 for P. afr. EA ranged 
from 0.156 mg/mL - 0.625 mg/mL, 0.0048 to 2.5 mg/mL for B. mic. EA, 0.078 to >0.625 mg/mL 
for B. mic A, 0.0098 to >5 mg/mL for metronidazole and 0.078 to >2.5 mg/mL for amoxicillin 
(Tables 5 & 6).  
At a concentration of 0.0098 mg/mL (MIC50), 10 (32.3%) of the 31 strains were inhibited by 
metronidazole followed by P. afr. EA, 8 (25.8%), and amoxicillin, 5 (16.1%). At 0.313 mg/mL, 
6 (19.4%) strains were inhibited by P. afr. EA and no activity was observed for both 
metronidazole and amoxicillin (Figure 3). Approximately, 48.4% of the strains were inhibited by 
B. mic. EA followed by amoxicillin, 12 (38.7%) and metronidazole, 11 (35.5%) at a 
concentration of 0.0048 mg/mL (MIC50). At 0.078 mg/mL, 11 (35.5%) strains were inhibited by 
B. mic A followed by amoxicillin, 6 (19.4%) and metronidazole, 5 (16.1%) (Figure 4). 
There was a statistical significant difference observed with potency of P. afr EA and B. mic. A 
compared to the two antibiotics at MIC50 (P < 0.05), but not for the antibiotics compared to each 
other (P > 0.05).  The activity of B. mic. EA was not statistically significant (P > 0.05) to the two 
antibiotics tested at 95% Confidence Interval (appendix 4). 
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Table 5: In-vitro anti-H. pylori activities of P. africanum EA extract and antibiotics at MIC50 
and MIC90 (mg/mL). 
 
              P.afr. (EA)                      Metronidazole                       Amoxicillin 
 
   H. pylori 
   strains             MIC50   MIC90        MIC50     MIC90         MIC50 MIC90 
         
PE11A 0.078 0.313 0.156 0.625 0.156 ND* 
PE26A 0.078 0.156 0.156 >0.625* 0.039 >0.313 
PE93A 0.078 ND 0.0098 ND 0.039 ND 
PE93C 0.313 ND 0.0195 ND 0.0048 >0.625 
PE102C 0.078 0.313 0.078 0.156 0.039 0.156 
PE115A 0.0098 >0.313 0.0098 ND 0.0098 ND 
PE155A 0.313 ND 0.0048 ND 0.0048 0.313 
PE162A 0.0098 >0.313 0.0048 ND 0.0048 0.078 
PE219C 0.0098 ND 0.0048 ND 0.078 0.313 
PE252C 0.313 >0.313 0.0098 ND 0.0098 ND 
PE258C 0.078 0.625 0.078 0.156 0.078 0.156 
PE265C 0.0048 ND 0.0048 ND 0.0048 1.25 
PE296C 0.0098 ND 0.0098 0.625 0.0048 0.156 
PE308C 0.0048 ND 0.0048 ND 0.0048 >0.625 
PE369A 0.156 ND 0.078 >5 0.078 >2.5 
PE369C 0.313 ND 0.0098 ND 0.0098 ND 
PE402A 0.078 >0.313 0.156 >0.156 0.078 >0.156 
PE406C 0.313 ND 0.0098 >5 0.0195 ND 
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PE407C 0.078 0.313 0.078 >0.156 0.039 0.625 
PE411C 0.0048 >0.313 0.0098 ND 0.0048 0.156 
PE430A 0.156 ND 0.0195 ND 0.039 0.156 
PE430C 0.156 ND 0.078 >5 0.078 >0.313 
PE436A 0.0098 ND 0.0048 ND  0.0048 ND 
PE436C 0.0098 ND 0.0048 0.0098  0.0048 0.625 
PE462A 0.313 ND 0.0098 ND  0.0098 ND 
PE462C 0.156 ND 0.0098 ND  0.0195 ND 
PE466C 0.039 >0.039 0.0098 ND  0.0098 ND 
PE467A 0.0048 >0.313 0.0048 ND  0.0048 0.625 
PE467C 0.0098 ND 0.0048 ND 0.078 0.313 
PE469C 0.0098 0.156 0.0048 1.25   0.0048 0.313 
PE471A         0.156 >0.313 0.0048 ND   0.0048 0.313 
         
Average      0.108      0.034   0.031  
 
*ND, Not determined; *>, Closer but not exact. 
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Table 6: In-vitro anti-H. pylori activities of B. micrantha EA extract and antibiotics at MIC50 
and MIC90 (mg/mL). 
 
 
B.mic. (EA) B.mic. (A) Metronidazole       Amoxicillin 
    
H. pylori        
strains 
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 
         
 PE11A   0.156 >0.625*  0.078  0.313 0.156 0.625 0.156   ND* 
 PE26A   0.078    >0.156      0.078     0.313    0.156    >0.625    0.039 >0.313 
 PE93A   0.039 ND 0.078 ND 0.0098 ND 0.039    ND 
 PE93C  0.0048 >0.0048 0.078 >0.313 0.0195 ND 0.0048  >0.625 
 PE102C   0.156 >0.625 0.078   0.313 0.078 0.156 0.039   0.156 
 PE115A   0.0195 ND 0.313 ND 0.0098 ND 0.0098    ND 
PE155A   0.0048 >0.0048 0.156 ND 0.0048 ND 0.0048   0.313 
PE162A   0.0048 >0.0048 0.078 >0.625 0.0048 ND 0.0048   0.078 
PE219C   0.0048 >0.0048 0.0048 >0.156 0.0048 ND 0.078   0.313 
PE252C   0.156 ND 0.313 ND 0.0098 ND 0.0098    ND 
PE258C   0.156 2.5 0.078 0.313 0.078 0.156 0.078   0.156 
PE265C   0.0048 >0.0048 0.156 ND 0.0048 ND 0.0048    1.25 
PE296C 0.0048 0.0048 0.0048 0.625 0.0098 0.625 0.0048   0.156 
PE308C 0.0048 >0.0048 0.078 ND 0.0048 ND 0.0048  >0.625 
PE369A    0.156 ND 0.156 ND 0.078 >5 0.078    >2.5 
PE369C 0.0098 >0.156 0.156 ND 0.0098 ND 0.0098     ND 
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PE402A    0.156 >1.25 0.078 0.625 0.156 >0.156 0.078  >0.156 
PE406C    0.078 ND 0.039 ND 0.0098 >5 0.0195     ND 
PE407C    0.156 1.25 0.078 0.313 0.078 >0.156 0.039    0.625 
PE411C 0.0048    >0.0048 0.313 ND 0.0098 ND 0.0048    0.156 
PE430A 0.0048 ND 0.313 >0.625 0.0195 ND 0.039    0.156 
PE430C    0.156 >0.156 0.156 ND 0.078 >5 0.078   >0.313 
PE436A 0.0048 >0.156 0.0098 >0.078 0.0048 ND 0.0048     ND 
PE436C 0.0048 0.0048 0.0098 0.625 0.0048 0.0098 0.0048    0.625 
PE462A    0.039 ND 0.313 ND 0.0098 ND 0.0098     ND 
PE462C 0.0195 ND 0.039 ND 0.0098 ND 0.0195     ND 
PE466C 0.0098 ND 0.156 ND 0.0098 ND 0.0098     ND 
PE467A 0.0048 >0.0098 0.039 >0.078 0.0048 ND 0.0048    0.625 
PE467C 0.0048 >0.0048 0.156 ND 0.0048 ND 0.078    0.313 
PE469C 0.0048 0.0048 0.0048 0.313 0.0048 1.25 0.0048    0.313 
PE471A 0.0048 >0.0048 0.078 >0.313 0.0048 ND 0.0048    0.313 
         
Average 0.052  0.118  0.034  0.031  
 
*ND, Not determined; *>, Closer but not exact. 
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*, No. of strains. 
Figure 3. Antibacterial profile (MIC50) of the tested extract (P. africanum) and antibiotics 
(metronidazole and amoxicillin) against 31 strains of H. pylori.  
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*, No. of strains. 
Figure 4. Antibacterial profile (MIC50) of the tested extract (B. micrantha) and antibiotics 
(metronidazole and amoxicillin) against 31 strains of H. pylori.  
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4.3 RATE OF KILL 
P. afr EA was active at a concentration of 0.05 mg/mL (½ x MIC), 0.2 mg/mL (2 x MIC) and 0.4 
mg/mL (4 x MIC) against strains PE466C and PE252C, while B. mic. EA was active at a 
concentration of 0.1 mg/mL (2 x MIC) and 0.2 mg/mL (4 x MIC) against strain PE430C and 
PE369C.  
We examined the killing curve time course of the extract at different concentrations. P. afr EA 
completely inhibited the growth of H. pylori strain PE466C at 0.1 mg/mL in 12 h and 0.4 mg/mL 
in 12 and 18 h of incubation. Growth was later observed from 24 to 60 h before permanent 
killing at 0.05 mg/mL in 66 h and 0.05 mg/mL & 0.2 mg/mL in 72 h respectively. For strain 
PE252C, complete inhibition was observed at 0.1 mg/mL and 0.4 mg/mL in 12 h, and at 0.2 
mg/mL in 24 h. One hundred percent killing effect was observed at 0.2 mg/mL in 66 h and at 
0.05 mg/mL, 0.1 mg/mL & 0.4 mg/mL in 72 h (Figures 5a and b).  
B. mic. EA completely inhibited the growth of H. pylori strain PE430C at all MIC concentrations 
in 12 h and at 0.1 mg/mL & 0.2 mg/mL in 18 & 24 h of incubation respectively. Growth and 
inhibition were later observed from 30 to 60 h before 100% killing at 0.1 mg/mL & 0.2 mg/mL 
in 66 and 72 h. Like strain PE430C, strain PE369C was totally inhibited at all the concentrations 
in 12 h. Inhibition was also observed at 0.1 mg/mL and 0.2 mg/mL in 54 & 66 h. One hundred 
percent killing was however observed at 0.1 mg/mL (2 x MIC) in 66 & 72 h (Figures 6a and b).  
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(a) 
 
(b) 
 
Figure 5. Profile of rate of kill of H. pylori strains (a) PE466C and (b) PE252C by ethyl acetate 
extract of P. africanum stem bark. 
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(a) 
 
(b) 
 
Figure 6. Profile of rate of kill of H. pylori strains (a) PE430C and (b) PE369C by ethyl acetate 
extract of B. micrantha stem bark. 
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4.4 PHYTOCHEMICAL COMPOUNDS 
Qualitative phytochemical analysis revealed the presence of flavonoids, steroids, tannins, 
alkaloids, and saponins. It was observed from the reactions (colours, heamolysis, turbidity, 
layers, emulsification and precipitation) that there may be much more of steroids, tannins, 
flavonoids, and saponins present in P. afr EA and B. mic. EA compared to alkaloids (table 7). 
 
Table 7: Qualitative analysis of the phytochemicals in the ethyl acetate extract of Peltophorum 
africanum and Bridelia micrantha. 
 
 
 
Phytochemical P. afr EA                      B. mic. EA 
Alkaloids     ++                                    ++ 
Flavonoids    +++                                  +++ 
Steroids    +++                                  +++ 
Tannins    +++                                  +++ 
Saponins    +++                                  +++ 
 
++, moderately present; +++, strongly present. 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSION 
5.1 DISCUSSION 
In spite of the high prevalence of H. pylori infection among gastric related morbidity patients in 
the Eastern Cape Province of South Africa, as well as the increasing trend of antibiotic resistant  
strains of this pathogen to the current treatment regimen (Tanih et al., 2010), few studies have 
examined the activities of medicinal plants used in Africa to treat infections symptomatic of this 
organism (Ndip et al., 2007; Njume et al., 2009). We are not aware of any study which evaluated 
the anti-H. pylori activity of P. africanum and B. micrantha in spite of its demonstrated 
antimicrobial potential against several microorganisms including Campylobacter spp with 
similar physiological characteristics to H. pylori (Samie et al., 2005). 
Resistance to metronidazole, clarithromycin and other antibiotic has been observed in different 
parts of the world and continue to increase; a major concern in the treatment of H. pylori 
infection which was also noted in this study. For example, strain PE296C observed to be 
resistant to metronidazole (Tanih et al., 2010) was also resistant to clarithromycin (0 mm) in the 
present study. The Gram-negative bacterial cell wall outer membrane and genetic make up are 
thought to act as a barrier to many substances including antibiotics. In contrast P. afr EA, B. mic. 
EA, B. mic. A, demonstrated activity against PE296C (and others) with high diameter zone of 
inhibition; 17 mm, 14 mm and 21 mm respectively and therefore makes these plants the subject 
of further studies. 
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Clarithromycin resistance to H. pylori observed in this study (41.9%) was similar to the finding 
reported by Gadhi et al. (2001), but higher compared to the study conducted by Cogo et al. 
(2010). The MIC50 of 0.034 mg/mL and 0.031 mg/mL were observed in this study for 
metronidazole and amoxicillin respectively (commercial antibiotics). This is expected to be more 
active compared with the crude extracts (P. afr EA 0.108 mg/mL, B. mic. EA 0.052 mg/mL and 
B. mic. A 0.118 mg/mL) used. The extracts were active with low MIC values which is in contrast 
with the study of Shikov et al. (2008) and Atapour et al. (2009) who reported high MIC values of 
their extracts.  
In the present study, the ethyl acetate and acetone extracts were observed to be the most active 
against all the H. pylori strains tested (P. afr EA, 100%; B. mic. EA, 93.5%; B. mic. A, 100%) 
compared with the other solvents used (figures 1 & 2). This is similar to the study of Theo et al. 
(2009) who demonstrated a good activity of the ethyl acetate extract of P. africanum against 
HIV-1. Maoela et al. (2009) worked on Carpobrotus mellei and Carpobrotus quadrifidus, 
common South African plants widely used in folk medicine and also reported marked activity 
with the ethyl acetate extract compared to  the chloroform and butanol extracts. Djipa et al. 
(2000) and Asha et al. (2008) reported potent antimicrobial activity of the acetone extract against 
pathogenic bacteria compared to other solvents used. This may be due to the fact that the active 
compounds against H. pylori strains in the plant were less polar, as ethyl acetate was the least 
polar followed by acetone among the solvents used. Non-polar solvents dissolve non-polar 
compounds best and different solvents extract different compounds. Organic solvents are better 
for more consistent extraction of antimicrobial substances from medicinal plants compared to 
other solvents (Abu-Shanab et al., 2006). 
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In the present study, these plants (stem bark) were observed to contain flavonoids, tannins, 
saponins, steroids and alkaloids which are the common compounds present in many active plants 
that had been reported by many investigators to possess antimicrobial property (Adegboye et al., 
2008). These phytochemical compounds are known to be biologically active and thus aid in the 
antimicrobial activities of many plants. Tannins for example, act by iron deprivation, hydrogen 
bounding or specific interactions with vital proteins such as enzymes and has been revealed for 
the treatment of inflamed or ulcerated tissues and remarkable activity in cancer prevention and 
anticancer (Li et al., 2003; Akinpelu et al., 2009). Flavonoids in the human diet may reduce the 
risk of various cancers, as well as preventing menopausal symptoms (Hodek et al., 2002). The 
huge increase in antioxidant capacity of blood seen after the consumption of flavonoid-rich foods 
is due to increased uric acid levels and so-called Phase II enzymes that also help to eliminate 
mutagens and carcinogens (Filippos et al., 2007).  
Saponins are known to produce an inhibitory effect on inflammation (Iwalewa et al., 2007) while 
alkaloids have been reported to have analgesic, anti-spasmodic and bactericidal effects; one of 
the most common biological properties of alkaloids is their toxicity against cells of foreign 
organisms. These activities have been widely studied for their potential use in the elimination 
and reduction of human cancer cell lines (Adegboye et al., 2008). All these facts support the 
usefulness of P. africanum and B. micrantha in folklore remedies and may be the reason these 
plants are widely used for the treatment of many diseases among many tribes in Africa.  Ali et al. 
(2005) had also documented compounds  including eugenol and cinnamaldehyde which at a  
concentration of 2 μg/ml completely inhibited all their H. pylori strains. It may therefore be the 
effects of these compounds that are responsible for the activities observed in the ethyl acetate 
and acetone extracts of P. africanum and B. micrantha tested in the present study. 
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Although the stem bark of P. africanum had not been previously investigated for its anti-H. 
pylori activity, it has  been shown to be active against a wide variety of bacteria  including 
Campylobacter spp, Bacillus cereus, Enterococcus fecalis, Staphylococcus aureus, Escherichia 
coli, Pseudomonas aeruginosa and Proteus mirabilis (Samie et al., 2005; Bessong et al., 2006; 
Samie et al., 2009). In the present study, the ethyl acetate extract of P. africanum demonstrated a 
zone of inhibition that ranged from 17 mm to 23 mm. On the other hand, the ethyl acetate extract 
of B. micrantha recorded a zone of inhibition that ranged from 12 mm to 20 mm, while 16 mm to 
23 mm was demonstrated by the acetone extract against this pathogen. This is remarkable and 
lays credence to similar diameter of zones of inhibition for ethyl acetate and other solvent 
extracts of some selected medicinal plants from Cameroon against H. pylori (Ndip et al., 2007).  
However, Adeleye et al. (2008) reported an inhibition zone diameter of 0 mm for the water 
extract of the leaves of B. micrantha against 0 mm to 15 mm reported in our study. This may be 
due to the fact that the different parts of the plant may contain varied phytochemicals. 
The MIC50 of the P. afr. EA extract ranged from 0.0048 – 0.313 mg/mL with a mean of 0.108 
mg/mL which is similar to the mean value of B. mic. A (0.118 mg/mL) but higher than the mean 
of B. mic. EA extract (0.052 mg/mL). Samie et al. (2005), found that P. africanum was active 
against B. cereus, E. faecalis, S. aureus, E. coli and P. aeruginosa with a MIC value that ranged 
between 1.5 - 12 mg/mL and that B. micrantha was mostly active against S. flexneri (1.5 mg/mL) 
and most other organisms tested with a MIC value that ranged between 3 to >12 mg/mL. This 
was less active compared to the result of this study. Adeleye et al. (2008) reported no activity for 
the water extract of the leaves of B. micrantha against H. pylori and a MIC of the ethanol extract 
of 40 mg/mL which is relatively high. We may ascribe these discrepancies to the different 
organisms used, season in which the plants were collected as well as storage conditions amongst 
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others as these factors have been reported to affect antimicrobial activity of even plants within 
the same species (Evans, 1996; WHO, 1992).  
However, in a similar study conducted by Ndip et al. (2007), MIC values which ranged from 
0.1698 mg/mL - 0.2336 mg/mL were obtained for the methanol extracts of the plants tested 
against H. pylori.  For all the isolates tested, the MIC50 of the control antibiotics ranged from 
0.0048 mg/mL (4.8 µg/mL) - 0.156 mg/mL (156 µg/mL) for amoxicillin and metronidazole 
respectively, which is  similar to a recent study in the same locality conducted by Tanih et al. 
(2010) who reported a MIC of 2.5 µg/mL - 5.0 µg/mL for amoxicillin. Metronidazole and 
amoxicillin which served as the positive control showed a significant difference (P < 0.05) in 
activity compared to P. africanum ethyl acetate & B. micrantha acetone extracts, but not (P > 
0.05) to B. micrantha ethyl acetate extract. 
Among all the strains investigated at MIC90, only strain PE258C had a concentration value of 
0.625 mg/mL (P. afr. EA); the others ranged between 0.0048 mg/mL to >0.313 mg/mL which 
reflects the highest concentration of killing effect observed at 0.4 mg/mL (4 x MIC). For B. mic. 
EA extract, apart from 5 strains with MIC90 >0.5 mg/mL others ranged from 0.0048 to >0.156; 
and therefore falls in line with the highest concentration of 0.2 mg/mL (4 x MIC) observed to 
have killed the organisms. This is in line with the study of Ali et al. (2005); and more potent 
compared to the observation reported by Gadhi et al. (2001). The organism was also noted to be 
completely killed when exposure time was increased to 66 and 72 h. From the observation, the 
rate of kill exhibited by the extract against the test strains were both concentration and time 
dependent which is in line with previous observations (Ali et al., 2005; Akinpelu et al., 2009). 
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The findings of this study revealed similar patterns of inhibition between the plant extracts and 
commercial antibiotics. For example, amoxicillin and metronidazole were more potent at the 
lowest concentration of 0.0048 mg/mL, than at higher concentrations. This also applied to P. afr. 
EA, B. mic. EA and B. mic A at 0.0098 mg/mL, 0.0048 mg/mL and 0.078 mg/mL respectively 
which is similar to the results of other investigators (Gadhi et al., 2001; Stamatis et al., 2003; 
Samie et al., 2009). 
Although the two plants tested in this study possessed anti-H. pylori activities, the index of their 
activities varied and may due to the solvents and crude extract used. For example, based on zone 
diameter of inhibition and susceptibility pattern, B. mic A (20.39±1.476; 100%) was more active 
than B. mic. EA (16.13±1.708; 93.5%). However, for MIC values, B. mic. EA extract was more 
active at a lower concentration, (0.0048 mg/mL) than B. mic A, (0.078 mg/mL) by inhibiting 
48.4% and 35.5% H. pylori strains respectively; this turn around in activity may due to the fact 
that the activity of extracts can be concentration dependent. This varied index in activity was also 
noted between B. mic. EA and P. afr. EA (zone diameter of inhibition, MIC and rate of kill). 
According to Uyub et al. (2010), it may not be known if the biological action, inhibitory and/or 
toxic activity is due to one or several compounds, although the isolation of pure compounds does 
not necessarily lead to an increase in inhibition as expected.  
According to Meining et al. (1998), like some other drugs, treatment with lansoprazole had no 
significant influence on the density of H. pylori colonization in the corpus but a significant 
decrease in the antrum was observed. Tanih et al. (2010) also observed a high resistance to most 
antibiotic tested against H. pylori strains in the corpus than antrum. Based on the results of this 
study, the most potent extracts were active to all the strains of H. pylori tested irrespective of 
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their site; antrum or corpus, even those resistant to the control antibiotics were susceptible. 
Hence these extracts may contain acid suppressing drug properties which has been suggested to 
correlate with efficacy in increasing gastric pH and therefore, results in reduction or eradication 
of H. pylori strains at the antrum (Meining et al., 1998). On the other hand the extracts may also 
possess properties using other mechanisms of action apart from acid suppressing property; as it 
has been reported that in the corpus there is a positive correlation between increasing pH and 
aggravation of inflammation, while in the antrum the correlation is the inverse of this (Meining 
et al., 1998). 
 
5.2 CONCLUSION 
Based on the findings of this study the following conclusions can be drawn: 
1. All the plants tested demonstrated anti-H. pylori activity with zone diameters of 
inhibition that ranged from 0 – 23 mm. 
2. The most potent extracts P. afr. EA, B. mic. EA and B. mic. A inhibited all the strains at a 
concentration of 0.108, 0.052 and 0.118 mg/mL respectively. 
3. The bactericidal activity investigated by the rate of kill showed P. afr. EA to be active at 
0.2 & 0.4 mg/mL and B. mic. EA at 0.1 & 0.2 mg/mL respectively. This was time and 
concentration dependent. 
4. Phytochemical analysis revealed the presence of flavonoids, tannins, saponins, steroids 
and alkaloids in P. afr. EA and B. mic. EA. 
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Ethical Clearance 
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Appendix 2 
Photographs of plant species, stomach ulcer and susceptibility plates 
 
Peltophorum africanum  
 
 
Bridelia micrantha  
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1. Esophagus 
2. Stomach 
3. Stomach ulcer                    
4. Duodenum (small intestine) 
 
Stomach ulcer 
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Susceptibility plates demonstrating zone of inhibition 
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Appendix 3 
Preparation of media used in the study 
Preparation of transport media 
The transport medium was composed of Brain Heart Infusion broth, glycerol and L-cysteine. 
Brain Heart Infusion broth was prepared following manufacturer‘s instruction which indicated 
37g/l of the broth. Glycerol (20%) was added and sterilized in an autoclave at 121
0
C for 
15minutes, then allowed to cool after which 2g/l of L-cysteine, non-animal source was added. 
 
Preparation of culture media 
The culture medium was composed of Columbia Blood Agar Base, selective supplement and 
horse blood. Columbia Blood Agar Base was prepared following manufacturer‘s instruction 
which indicated 39g/l of the agar. The mixture was boiled to dissolve and sterilized in an 
autoclave at 121
0
C for 15minutes. It was allowed to cool (50
0
C), after which 2ml and 35ml (7%) 
of selective supplement and horse blood were added respectively. 
 
Preparation of Urea Agar Base media 
The Urea Agar Base medium was composed of Urea Agar Base and urea. Urea Agar Base was 
prepared following manufacturer‘s instruction which indicated 25.3g/l of the agar and sterilized 
in an autoclave at 121
0
C for 15minutes. It was allowed to cool (50
0
C) and an ampoule of urea 
(40%) was added. 
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Preparation of Brain Heart Infusion Agar 
The culture medium was composed of Brain Heart Infusion Agar, selective supplement and 
horse blood. Brain Heart Infusion Agar was prepared following manufacturer‘s instruction which 
indicated 47g/l of the agar. The mixture was boiled to dissolve and sterilized in an autoclave at 
121
0
C for 15minutes. It was allowed to cool (50
0
C), after which 2ml and 35ml (7%) of selective 
supplement and horse blood were added respectively. 
 
Preparation of storage media 
Storage media was composed of Brain Heart Infusion Broth (BHI), Glycerol and Distilled water. 
This was prepared by diluting 20% glycerol in distilled water containing BHI broth following 
manufacturer instructions as described above and then sterilized in an autoclave at 121
0
C for 
15minutes. It was stored at -80
0
C until use. 
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Appendix 4 
Statistical observations 
P. africanum and antibiotic: comparison of zone diameters (SPSS Version 17.0, 
ONE   WAY ANOVA) 
 
 
Multiple Comparisons 
ZD 
Tukey HSD 
(I) ET (J) ET 
Mean 
Difference (I-
J) Std. Error Sig.* 
95% Confidence Interval 
Lower Bound Upper Bound 
1* 2 11.355
*
 1.152 .000 8.04 14.67 
3 9.677
*
 1.152 .000 6.36 13.00 
4 8.226
*
 1.152 .000 4.91 11.54 
5 8.258
*
 1.152 .000 4.94 11.58 
6 4.032
*
 1.152 .008 .71 7.35 
2 1 -11.355
*
 1.152 .000 -14.67 -8.04 
3 -1.677 1.152 .693 -5.00 1.64 
4 -3.129 1.152 .077 -6.45 .19 
5 -3.097 1.152 .083 -6.42 .22 
6 -7.323
*
 1.152 .000 -10.64 -4.00 
3 1 -9.677
*
 1.152 .000 -13.00 -6.36 
2 1.677 1.152 .693 -1.64 5.00 
4 -1.452 1.152 .806 -4.77 1.87 
5 -1.419 1.152 .821 -4.74 1.90 
6 -5.645
*
 1.152 .000 -8.96 -2.33 
4 1 -8.226
*
 1.152 .000 -11.54 -4.91 
2 3.129 1.152 .077 -.19 6.45 
3 1.452 1.152 .806 -1.87 4.77 
5 .032 1.152 1.000 -3.29 3.35 
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6 -4.194
*
 1.152 .005 -7.51 -.87 
5 1 -8.258
*
 1.152 .000 -11.58 -4.94 
2 3.097 1.152 .083 -.22 6.42 
3 1.419 1.152 .821 -1.90 4.74 
4 -.032 1.152 1.000 -3.35 3.29 
6 -4.226
*
 1.152 .004 -7.54 -.91 
6 1 -4.032
*
 1.152 .008 -7.35 -.71 
2 7.323
*
 1.152 .000 4.00 10.64 
3 5.645
*
 1.152 .000 2.33 8.96 
4 4.194
*
 1.152 .005 .87 7.51 
5 4.226
*
 1.152 .004 .91 7.54 
*, The mean difference is significant at the <0.05 level; 1, P. afr. EA; 2, P. afr. A; 3, P. afr. E; 
4, P. afr. M; 5, P. afr. W; 6, Clar. 
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B. micrantha and antibiotic: comparison of zone diameters (SPSS Version 17.0, 
ONE   WAY ANOVA) 
 
 
Multiple Comparisons 
ZD 
Tukey HSD 
(I) ET (J) ET 
Mean 
Difference (I-
J) Std. Error Sig.* 
95% Confidence Interval 
Lower Bound Upper Bound 
1* 2 -4.258
*
 1.191 .006 -7.69 -.83 
3 13.387
*
 1.191 .000 9.96 16.82 
4 10.452
*
 1.191 .000 7.02 13.88 
5 5.097
*
 1.191 .000 1.67 8.53 
6 .806 1.191 .984 -2.62 4.24 
2 1 4.258
*
 1.191 .006 .83 7.69 
3 17.645
*
 1.191 .000 14.22 21.08 
4 14.710
*
 1.191 .000 11.28 18.14 
5 9.355
*
 1.191 .000 5.92 12.78 
6 5.065
*
 1.191 .000 1.63 8.49 
3 1 -13.387
*
 1.191 .000 -16.82 -9.96 
2 -17.645
*
 1.191 .000 -21.08 -14.22 
4 -2.935 1.191 .140 -6.37 .49 
5 -8.290
*
 1.191 .000 -11.72 -4.86 
6 -12.581
*
 1.191 .000 -16.01 -9.15 
4 1 -10.452
*
 1.191 .000 -13.88 -7.02 
2 -14.710
*
 1.191 .000 -18.14 -11.28 
3 2.935 1.191 .140 -.49 6.37 
5 -5.355
*
 1.191 .000 -8.78 -1.92 
6 -9.645
*
 1.191 .000 -13.08 -6.22 
5 1 -5.097
*
 1.191 .000 -8.53 -1.67 
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2 -9.355
*
 1.191 .000 -12.78 -5.92 
3 8.290
*
 1.191 .000 4.86 11.72 
4 5.355
*
 1.191 .000 1.92 8.78 
6 -4.290
*
 1.191 .005 -7.72 -.86 
6 1 -.806 1.191 .984 -4.24 2.62 
2 -5.065
*
 1.191 .000 -8.49 -1.63 
3 12.581
*
 1.191 .000 9.15 16.01 
4 9.645
*
 1.191 .000 6.22 13.08 
5 4.290
*
 1.191 .005 .86 7.72 
*, The mean difference is significant at the <0.05 level; 1, B. mic. EA; 2, B. mic. A; 3, B. mic.  
E; 4, B. mic. M; 5, B. mic. W; 6, Clar. 
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P. africanum and antibiotic: comparison of MIC50 (SPSS Version 17.0, ONE   WAY ANOVA) 
 
 
Multiple Comparisons 
MI 
Tukey HSD 
(I) ET (J) ET 
Mean 
Difference (I-
J) Std. Error Sig.* 
95% Confidence Interval 
Lower Bound Upper Bound 
1* 2 .073961
*
 .019015 .001 .02865 .11928 
3 .076645
*
 .019015 .000 .03133 .12196 
2 1 -.073961
*
 .019015 .001 -.11928 -.02865 
3 .002684 .019015 .989 -.04263 .04800 
3 1 -.076645
*
 .019015 .000 -.12196 -.03133 
2 -.002684 .019015 .989 -.04800 .04263 
*, The mean difference is significant at the <0.05 level; 1, P. afr. EA; 2, Metro; 3, Amox. 
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B. micrantha and antibiotic: comparison of MIC50 (SPSS Version 17.0, ONE   
WAY ANOVA) 
 
Multiple Comparisons 
MI 
Tukey HSD 
(I) ET (J) ET 
Mean 
Difference (I-
J) Std. Error Sig.* 
95% Confidence Interval 
Lower Bound Upper Bound 
1* 2 -.066239
*
 .016970 .001 -.11045 -.02202 
3 .018219 .016970 .706 -.02599 .06243 
4 .020903 .016970 .608 -.02331 .06512 
2 1 .066239
*
 .016970 .001 .02202 .11045 
3 .084458
*
 .016970 .000 .04024 .12867 
4 .087142
*
 .016970 .000 .04293 .13136 
3 1 -.018219 .016970 .706 -.06243 .02599 
2 -.084458
*
 .016970 .000 -.12867 -.04024 
4 .002684 .016970 .999 -.04153 .04690 
4 1 -.020903 .016970 .608 -.06512 .02331 
2 -.087142
*
 .016970 .000 -.13136 -.04293 
3 -.002684 .016970 .999 -.04690 .04153 
*, The mean difference is significant at the <0.05 level; 1, B. mic. EA; 2, B. mic. A; 3, Metro; 4, 
Amox. 
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B. micrantha and P. africanum: comparison of MIC50 (SPSS Version 17.0, 
ONE   WAY ANOVA) 
 
 
 
Multiple Comparisons 
MI 
Tukey HSD 
(I) ET (J) ET 
Mean 
Difference (I-
J) Std. Error Sig.* 
95% Confidence Interval 
Lower Bound Upper Bound 
1* 2 .055742 .024248 .061 -.00204 .11353 
3 -.010497 .024248 .902 -.06828 .04729 
2 1 -.055742 .024248 .061 -.11353 .00204 
3 -.066239
*
 .024248 .021 -.12402 -.00845 
3 1 .010497 .024248 .902 -.04729 .06828 
2 .066239
*
 .024248 .021 .00845 .12402 
*, The mean difference is significant at the <0.05 level; 1, P. afr. EA; 2, B. mic. EA; 3, B. mic. 
A. 
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Appendix 5 
Publications and manuscript submitted 
Okeleye BI, Samie A, Bessong PO, Mkwetshana NF, Green E, Clarke AM, Ndip RN. (2010). 
Crude Ethyl Acetate Extract of the Stem Bark of Peltophorum africanum (Sond, Fabaceae) 
possesses in vitro inhibitory and bactericidal activity against clinical isolates of Helicobacter 
pylori. Journal of Medicinal Plants Research. 4 (14): 1432-1440. 
Okeleye BI, Mkwetshana NF, Samie A, Bessong PO, Green E, Ndip RN. (2010). In vitro anti-
Helicobacter pylori activities of crude ethyl acetate extract of the stem bark of Bridelia 
micrantha (Hochst., Baill., Euphorbiaceae): Preliminary phytochemical screenings. Submitted to 
African Journal of Traditional, Complementary and Alternative Medicines. 
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